Drug;Gene;Genotype;Alleles;Outcome;Variation;Effect;Entity
KETANSERIN;HTR1B;rs130060;C;LADME-PD;DECREASED_AFFINITY;;HTR1B
THIOXANTHINE;XDH;rs2295474;T;LADME-PK;DECREASED_CLEARANCE;;XDH
PAROMOMYCIN;MT-RNR1;rs267606617;G;LADME-PD;DECREASED_ACTIVITY;;MT-RNR1
THIOXANTHINE;XDH;rs45442092;T;LADME-PK;DECREASED_CLEARANCE;;XDH
DIHYDROERGOTAMINE, METHYSERGIDE, SUMATRIPTAN;HTR1B;rs130060;C;LADME-PD;INCREASED_AFFINITY;;HTR1B
FLUOROURACIL;TYMS;rs45445694;(CCGCGCCACTTGGCCTGCCTCCGTCCCG)3/(CCGCGCCACTTGGCCTGCCTCCGTCCCG)3;LADME-PK;INCREASED_EXPRESSION;;TYMS
CISPLATIN, IRINOTECAN;UBE2I;rs9597;CG;LADME-PK;INCREASED_EXPRESSION;;SAE1
METHOTREXATE;SHMT1;rs1979277;AA;LADME-PK;INCREASED_CATALYTIC_ACTIVITY;;TYMS
IVACAFTOR;CFTR;rs113993960;del;EFFICACY;ACTIVITY;;CFTR
IVACAFTOR;CFTR;rs397508139;A;EFFICACY;ACTIVITY;;CFTR
FLUOROURACIL;DPYD;rs1335150891;C;LADME-PK;DECREASED_CATALYTIC_ACTIVITY;INCREASED_RISK;DPYD
IVACAFTOR;CFTR;rs141033578;T;EFFICACY;ACTIVITY;;CFTR
IVACAFTOR;CFTR;rs121909011;T;EFFICACY;ACTIVITY;;CFTR
IVACAFTOR;CFTR;rs77409459;T;EFFICACY;ACTIVITY;;CFTR
IVACAFTOR;CFTR;rs397508510;C;EFFICACY;ACTIVITY;;CFTR
PHENYTOIN;CYP2C9;rs12782374;A;;DECREASED_EXPRESSION;;ENZYME:CYP2C9
IVACAFTOR;CFTR;rs397508435;C;EFFICACY;ACTIVITY;;CFTR
IVACAFTOR;CFTR;rs77010898;A;EFFICACY;INCREASED_ACTIVITY;;CFTR
ESTRADIOL;TCL1A;rs7158782;G;OTHER;INCREASED_EXPRESSION;;IL17RA
IVACAFTOR;CFTR;rs397508328;G;EFFICACY;ACTIVITY;;CFTR
IVACAFTOR;CFTR;rs77932196;A;EFFICACY;ACTIVITY;;CFTR
NIMESULIDE;PTGS2;rs5272;C;LADME-PK;INCREASED_ENZYME_ACTIVITY;;PTGS2
IVACAFTOR;CFTR;rs75527207;A;EFFICACY;ASSOCIATED_PROTEIN-STABILITY;;CFTR
IVACAFTOR;CFTR;rs1800111;C;EFFICACY;ACTIVITY;;CFTR
IVACAFTOR;CFTR;rs74551128;A;EFFICACY;ACTIVITY;;CFTR
IVACAFTOR;CFTR;rs186045772;A;EFFICACY;ACTIVITY;;CFTR
IVACAFTOR;CFTR;rs78769542;A;EFFICACY;ACTIVITY;;CFTR
IVACAFTOR;CFTR;rs397508537;A;EFFICACY;ACTIVITY;;CFTR
IVACAFTOR;CFTR;rs397508256;A;EFFICACY;ACTIVITY;;CFTR
IVACAFTOR;CFTR;rs121908751;A;EFFICACY;ACTIVITY;;CFTR
IVACAFTOR;CFTR;rs75527207;A;EFFICACY;ACTIVITY;;CFTR
CISPLATIN;TPMT;TPMT*1, TPMT*3A;*3A;OTHER;INCREASED_EXPRESSION;;TLR4
IVACAFTOR;CFTR;rs368505753;T;EFFICACY;ACTIVITY;;CFTR
NIMESULIDE;PTGS2;rs5273;G;LADME-PK;INCREASED_ENZYME_ACTIVITY;;PTGS2
IVACAFTOR;CFTR;rs115545701;T;EFFICACY;ACTIVITY;;CFTR
SACUBITRIL;CES1;rs71647871;CT;EFFICACY;DECREASED_CATALYTIC_ACTIVITY;INCREASED_RISK;CES1
IVACAFTOR;CFTR;rs1800100;T;EFFICACY;ACTIVITY;;CFTR
ESTRADIOL;TCL1A;rs7158782;A;OTHER;INCREASED_EXPRESSION;;IL12RB2
ESTRADIOL;TCL1A;rs7158782;G;OTHER;INCREASED_EXPRESSION;;TCL1A
ANASTROZOLE, EXEMESTANE, LETROZOLE;CYP19A1;rs6493497;AG;OTHER;ACTIVITY;;CYP19A1
ANASTROZOLE, EXEMESTANE, LETROZOLE;CYP19A1;rs7176005;CT;OTHER;ACTIVITY;;CYP19A1
MERCAPTOPURINE, THIOGUANINE;TPMT;TPMT*1, TPMT*2, TPMT*3A, TPMT*3C, TPMT*9, TPMT*21, TPMT*32, TPMT*33, TPMT*34;*1/*2 + *1/*3A + *1/*3C + *1/*9 + *1/*21 + *1/*32 + *1/*33 + *1/*34;LADME-PK;DECREASED_ACTIVITY;DRUG_ACCUMULATION;TPMT
SITAGLIPTIN;DPP4;rs759717;CC;LADME-PD;INCREASED_ACTIVITY;;DPP4
SITAGLIPTIN;DPP4;rs2909451;TT;LADME-PD;INCREASED_ACTIVITY;;DPP4
TAMOXIFEN;CYP2D6;CYP2D6*1, CYP2D6*5, CYP2D6*10, CYP2D6*14, CYP2D6*18, CYP2D6*21, CYP2D6*41;*5/*10 + *5/*21 + *41/*41 + *10/*10 + *10/*41;EFFICACY;INCREASED_EXPRESSION;;MKI67
ESTRADIOL;TCL1A;rs7158782;A;OTHER;INCREASED_EXPRESSION;;IL1R2
ESTRADIOL;TCL1A;rs7158782;A;OTHER;INCREASED_EXPRESSION;;IL17A
ESTRADIOL;TCL1A;rs7159713;A;OTHER;INCREASED_EXPRESSION;;IL1R2
ESTRADIOL;TCL1A;rs7159713;A;OTHER;INCREASED_EXPRESSION;;IL12RB2
ESTRADIOL;TCL1A;rs7159713;A;OTHER;INCREASED_EXPRESSION;;IL17A
ESTRADIOL;TCL1A;rs7159713;G;OTHER;INCREASED_EXPRESSION;;TCL1A
IVACAFTOR;CFTR;rs78655421;A;EFFICACY;ACTIVITY;;CFTR
IVACAFTOR;CFTR;rs397508759;A;EFFICACY;ACTIVITY;;CFTR
IVACAFTOR;CFTR;rs150212784;G;EFFICACY;ACTIVITY;;CFTR
IVACAFTOR;CFTR;rs34911792;G;EFFICACY;ACTIVITY;;CFTR
IVACAFTOR;CFTR;rs397508513;C;EFFICACY;ACTIVITY;;CFTR
ESTRADIOL;TCL1A;rs7159713;G;OTHER;INCREASED_EXPRESSION;;IL17RA
METHOXSALEN;CYP2A6;CYP2A6*15, CYP2A6*21, CYP2A6*22;*15 + *21 + *22;OTHER;DECREASED_ENZYME_ACTIVITY;;CYP2A6
ATORVASTATIN;SCAP;rs12487736;TT;OTHER;DECREASED_TRANSCRIPTION;;GENE:SCAP
IVACAFTOR;CFTR;rs202179988;T;EFFICACY;ACTIVITY;;CFTR
TAMOXIFEN;CYP2D6;CYP2D6*1, CYP2D6*2;*2;OTHER;DECREASED_ACTIVITY;;CYP2D6
VITAMIN E;CYP4F2;rs3093105;C;LADME-PK;INCREASED_CATALYTIC_ACTIVITY;;CYP4F2
ESTRADIOL;;rs11849538;C;OTHER;INCREASED_EXPRESSION;;IL17A
ESTRADIOL;;rs11849538;C;OTHER;INCREASED_EXPRESSION;;IL1R2
IVACAFTOR / LUMACAFTOR;CFTR;rs78655421;A;EFFICACY;INCREASED_ACTIVITY;;CFTR
IVACAFTOR, NPPB;CFTR;rs75527207;A;EFFICACY;INCREASED_ACTIVITY;;CFTR
EFAVIRENZ;CYP2B6;CYP2B6*6;*6;LADME-PK;INCREASED_ACTIVITY;;CYP3A4
FLUOROURACIL;DPYD;rs56005131;T;LADME-PK;DECREASED_CATALYTIC_ACTIVITY;INCREASED_RISK;DPYD
ESTRADIOL;;rs2369049;G;OTHER;INCREASED_EXPRESSION;;IL17RA
ESTRADIOL;;rs2369049;A;OTHER;INCREASED_EXPRESSION;;IL12RB2
ESTRADIOL;;rs2369049;A;OTHER;INCREASED_EXPRESSION;;IL17A
ELEXACAFTOR / TEZACAFTOR / IVACAFTOR;CFTR;rs80034486;CG;LADME-PD;INCREASED_ACTIVITY;;CFTR
CORR-4A, IVACAFTOR, LUMACAFTOR;CFTR;rs113993960;del/del;EFFICACY;INCREASED_ACTIVITY;;CFTR
ESTRADIOL;;rs2369049;A;OTHER;INCREASED_EXPRESSION;;IL1R2
IVACAFTOR;CFTR;rs397508288;G;EFFICACY;ACTIVITY;;CFTR
IVACAFTOR;CFTR;rs75541969;C;EFFICACY;ACTIVITY;;CFTR
ESCITALOPRAM;IL11;rs1126757;CT + TT;OTHER;DECREASED_EXPRESSION;;IL11
ESTRADIOL;;rs11849538;G;OTHER;INCREASED_EXPRESSION;;TCL1A
METHOTREXATE;FASTKD3, MTRR;rs1801394;AG + GG;;INCREASED_CATALYTIC_ACTIVITY;;TYMS
ESTRADIOL;;rs11849538;G;OTHER;INCREASED_EXPRESSION;;IL17RA
ESTRADIOL;;rs11849538;C;OTHER;INCREASED_EXPRESSION;;IL12RB2
IVACAFTOR;CFTR;rs11971167;T;EFFICACY;ACTIVITY;;CFTR
ESTRADIOL;;rs2369049;G;OTHER;INCREASED_EXPRESSION;;TCL1A
IVACAFTOR;CFTR;rs121909019;A;EFFICACY;ACTIVITY;;CFTR
IVACAFTOR;CFTR;rs121908753;A;EFFICACY;ACTIVITY;;CFTR
PHENYTOIN;CYP2C9;rs71486745;del;;DECREASED_EXPRESSION;;ENZYME:CYP2C9
METHOTREXATE;MTHFR;rs1801131;GT;;INCREASED_CATALYTIC_ACTIVITY;;TYMS
IVACAFTOR;CFTR;rs77834169;T;EFFICACY;ACTIVITY;;CFTR
IVACAFTOR;CFTR;rs397508442;T;EFFICACY;ACTIVITY;;CFTR
IVACAFTOR;CFTR;rs121909047;A;EFFICACY;ACTIVITY;;CFTR
GLYBURIDE;KCNJ11;rs5219;T;LADME-PK;DECREASED_ACTIVITY;DRUG_ACCUMULATION;KCNJ11
HYDROCHLOROTHIAZIDE;YEATS4;rs7297610;CC;LADME-PK;DECREASED_EXPRESSION;;YEATS4
IVACAFTOR;CFTR;rs121908752;G;EFFICACY;ACTIVITY;;CFTR
IVACAFTOR;CFTR;rs75527207;A;EFFICACY;INCREASED_ACTIVITY;;CFTR
VITAMIN E;CYP4F2;rs2108622;T;OTHER;DECREASED_ENZYME_ACTIVITY;;CYP4F2
IVACAFTOR;CFTR;rs121909020;A;EFFICACY;ACTIVITY;;CFTR
IVACAFTOR;CFTR;rs113993958;C;EFFICACY;ACTIVITY;;CFTR
DISOPYRAMIDE;KCNH2;rs104894021;T;EFFICACY;DECREASED_INHIBITION;;KCNH2
MEPHENYTOIN;CYP2C19;CYP2C19*1, CYP2C19*10;*10;LADME-PK;DECREASED_CATALYTIC_ACTIVITY;INCREASED_RISK;ENZYME:CYP2C19
QUINIDINE;KCNH2;rs104894021;T;EFFICACY;DECREASED_INHIBITION;;KCNH2
CHLOROCRESOL;RYR1;rs193922803;T;OTHER;INCREASED_ACTIVITY;;RYR1
TAMOXIFEN;NCOA1;rs1804645;T;;DECREASED_ACTIVITY;;NCOA1
CYTARABINE;CDA;rs60369023;AA + AG;LADME-PK;DECREASED_CATALYTIC_ACTIVITY;INCREASED_RISK;CDA
GENTAMICIN;MT-RNR1;rs267606619;T;LADME-PD;DECREASED_ACTIVITY;;MT-RNR1
QUINIDINE;KCNH2;rs104894021;C;EFFICACY;DECREASED_INHIBITION;;KCNH2
BUPROPION;CYP2B6;CYP2B6*1, CYP2B6*30;*1/*30;OTHER;DECREASED_ACTIVITY;;CYP2B6
GEMCITABINE;DCTD;rs35932500;C;LADME-PK;DECREASED_ENZYME_ACTIVITY;;DCTD
BUPROPION;POR;rs2868177;AG + GG;LADME-PK;INCREASED_ACTIVITY;;CYP2B6
GEMCITABINE;CDA;rs2072671;C;LADME-PK;DECREASED_ENZYME_ACTIVITY;;CDA
ADALIMUMAB;TNF;rs1800629;AG;LADME-PK;DECREASED_STEADY-STATE-LEVEL;;TNF
PAROMOMYCIN;MT-RNR1;rs267606617;G;LADME-PD;DECREASED_ACTIVITY;;MT-RNR1
SIMVASTATIN;HLA-G;rs1063320;GG;OTHER;INCREASED_EXPRESSION;;HLA-G
ACETAMINOPHEN;CYP2E1;rs2515641;T;OTHER;INCREASED_EXPRESSION;;CYP2E1
MEPHENYTOIN;CYP2C19;CYP2C19*1, CYP2C19*19;*19;OTHER;DECREASED_CATALYTIC_ACTIVITY;INCREASED_RISK;ENZYME:CYP2C19
BUPRENORPHINE;OPRM1;rs1799971;G;EFFICACY;DECREASED_ACTIVITY;;OPRM1
TAMOXIFEN;UGT1A4;rs8330;CC;LADME-PK;DECREASED_ACTIVITY;DRUG_ACCUMULATION;UGT1A4
OMEPRAZOLE;CYP2C19;CYP2C19*1, CYP2C19*19;*19;LADME-PK;INCREASED_CATALYTIC_ACTIVITY;;ENZYME:CYP2C19
CLOPIDOGREL;CYP2C19;CYP2C19*1, CYP2C19*28;*28;LADME-PK;INCREASED_CATALYTIC_ACTIVITY;;ENZYME:CYP2C19
GEMCITABINE;FKBP5;rs73748206;CT;OTHER;INCREASED_EXPRESSION;;FKBP5
MEPHENYTOIN;CYP2C19;CYP2C19*1, CYP2C19*10, CYP2C19*14, CYP2C19*19, CYP2C19*25, CYP2C19*26;*10 + *14 + *19 + *25 + *26;LADME-PK;DECREASED_CATALYTIC_ACTIVITY;INCREASED_RISK;ENZYME:CYP2C19
CLOPIDOGREL;CYP2C19;CYP2C19*1, CYP2C19*10, CYP2C19*13, CYP2C19*14, CYP2C19*15, CYP2C19*18, CYP2C19*19, CYP2C19*23, CYP2C19*25, CYP2C19*26;*10 + *13 + *14 + *15 + *18 + *19 + *23 + *25 + *26;LADME-PK;DECREASED_CATALYTIC_ACTIVITY;INCREASED_RISK;ENZYME:CYP2C19
MEPHENYTOIN, OMEPRAZOLE;CYP2C19;CYP2C19*1, CYP2C19*26;*26;LADME-PK;DECREASED_CATALYTIC_ACTIVITY;INCREASED_RISK;ENZYME:CYP2C19
ACETAMINOPHEN;UGT1A;rs8330;CC;LADME-PK;DECREASED_ACTIVITY;DRUG_ACCUMULATION;UGT1A
ETHANOL;ADH1B;rs1229984;CT + TT;LADME-PK;INCREASED_ENZYME_ACTIVITY;;ADH1B
ELEXACAFTOR, IVACAFTOR, TEZACAFTOR;CFTR;rs113993960;del/del;OTHER;INCREASED_TRANSPORT;;CFTR
ACETAMINOPHEN;UGT1A;rs10929303;CC;LADME-PK;DECREASED_ACTIVITY;DRUG_ACCUMULATION;UGT1A
XENOBIOTICS;AHR;rs2066853;A;LADME-PK;INCREASED_EXPRESSION;;CYP1A1
OMEPRAZOLE, XENOBIOTICS;AHR;rs75519181;G;LADME-PK;DECREASED_EXPRESSION;;CYP1A1
ACETAMINOPHEN;UGT1A;rs1042640;CC;LADME-PK;DECREASED_ACTIVITY;DRUG_ACCUMULATION;UGT1A
GEMCITABINE;FKBP5;rs73748206;CT;OTHER;INCREASED_EXPRESSION;;NR3C1
ESTRADIOL;;rs3802201;GG;OTHER;INCREASED_EXPRESSION;;MIR2052
ALDOSTERONE, INSULIN RECOMBINANT;SCNN1B;rs34241435;A;OTHER;INCREASED_TRANSCRIPTION;;GENE:SCNN1B
ESTRADIOL;;rs4476990;CC;OTHER;INCREASED_EXPRESSION;;MIR2052
MEPHENYTOIN;CYP2C19;CYP2C19*1, CYP2C19*9;*9;LADME-PK;DECREASED_ACTIVITY;DRUG_ACCUMULATION;ENZYME:CYP2C19
MEPHENYTOIN;CYP2C19;CYP2C19*1, CYP2C19*10;*10;LADME-PK;DECREASED_ACTIVITY;DRUG_ACCUMULATION;ENZYME:CYP2C19
BERBERINE, COPTISINE;CYP2D6;CYP2D6*1;*1/*1;LADME-PK;INCREASED_INHIBITION;;CYP2D6
3-CYANO-7-ETHOXYCOUMARIN;CYP2C19;CYP2C19*1, CYP2C19*8, CYP2C19*10;*8 + *10;LADME-PK;DECREASED_CATALYTIC_ACTIVITY;INCREASED_RISK;ENZYME:CYP2C19
MEPHENYTOIN;CYP2C19;CYP2C19*1, CYP2C19*23;*23;LADME-PK;INCREASED_CATALYTIC_ACTIVITY;;ENZYME:CYP2C19
BERBERINE, COPTISINE;CYP2D6;CYP2D6*1, CYP2D6*10;*1/*10;LADME-PK;INCREASED_INHIBITION;;CYP2D6
DISOPYRAMIDE;KCNH2;rs104894021;C;EFFICACY;DECREASED_INHIBITION;;KCNH2
IVACAFTOR;CFTR;rs74503330;A;OTHER;INCREASED_ACTIVITY;;CFTR
FLUOROURACIL;DPYD;rs372307932;T;LADME-PK;DECREASED_ACTIVITY;DRUG_ACCUMULATION;ENZIME:DPD
MIDAZOLAM;CYP3A4;rs35599367;AG;LADME-PK;DECREASED_ACTIVITY;DRUG_ACCUMULATION;CYP3A4
DEXTROMETHORPHAN;CYP3A4;rs35599367;AG;LADME-PK;DECREASED_ACTIVITY;DRUG_ACCUMULATION;CYP3A4
MEPHENYTOIN;CYP2C19;CYP2C19*1, CYP2C19*10;*10;LADME-PK;DECREASED_ACTIVITY;DRUG_ACCUMULATION;ENZYME:CYP2C19
MEPHENYTOIN, OMEPRAZOLE;CYP2C19;CYP2C19*1, CYP2C19*16;*16;LADME-PK;DECREASED_ACTIVITY;DRUG_ACCUMULATION;ENZYME:CYP2C19
MEPHENYTOIN;CYP2C19;CYP2C19*1, CYP2C19*19;*19;LADME-PK;DECREASED_ACTIVITY;DRUG_ACCUMULATION;ENZYME:CYP2C19
MEPHENYTOIN;CYP2C19;CYP2C19*1, CYP2C19*18;*18;LADME-PK;DECREASED_ACTIVITY;DRUG_ACCUMULATION;ENZYME:CYP2C19
FLUOROURACIL;DPYD;rs376073289;T;LADME-PK;DECREASED_ACTIVITY;DRUG_ACCUMULATION;ENZIME:DPD
FLUOROURACIL;DPYD;rs374527058;G;LADME-PK;DECREASED_ACTIVITY;DRUG_ACCUMULATION;ENZIME:DPD
FLUOROURACIL;DPYD;rs538336580;A;LADME-PK;DECREASED_ACTIVITY;DRUG_ACCUMULATION;ENZIME:DPD
MEPHENYTOIN, OMEPRAZOLE;CYP2C19;CYP2C19*1, CYP2C19*9;*9;LADME-PK;DECREASED_ACTIVITY;DRUG_ACCUMULATION;ENZYME:CYP2C19
FLUOROURACIL;DPYD;rs568367673;A;LADME-PK;DECREASED_ACTIVITY;DRUG_ACCUMULATION;ENZIME:DPD
FLUOROURACIL;DPYD;rs558354142;A;LADME-PK;DECREASED_ACTIVITY;DRUG_ACCUMULATION;ENZIME:DPD
MEPHENYTOIN, OMEPRAZOLE;CYP2C19;rs770829708;A;LADME-PK;DECREASED_ACTIVITY;DRUG_ACCUMULATION;ENZYME:CYP2C19
FLUOROURACIL;DPYD;rs374825099;T;LADME-PK;DECREASED_ACTIVITY;DRUG_ACCUMULATION;ENZIME:DPD
ESTRONE SULFATE, ROSUVASTATIN;SLCO2B1;rs199654337;T;LADME-PK;DECREASED_TRANSPORT;;SLCO2B1
MEPHENYTOIN, OMEPRAZOLE;CYP2C19;CYP2C19*1, CYP2C19*9, CYP2C19*10, CYP2C19*16;*9 + *10 + *16;LADME-PK;DECREASED_CLEARANCE;;ENZYME:CYP2C19
OMEPRAZOLE;CYP2C19;CYP2C19*1, CYP2C19*19;*19;LADME-PK;DECREASED_CLEARANCE;;ENZYME:CYP2C19
ESTRONE SULFATE, ROSUVASTATIN;SLCO2B1;rs1009122956;C;LADME-PK;DECREASED_TRANSPORT;;SLCO2B1
ESTRONE SULFATE, ROSUVASTATIN;SLCO2B1;rs1621378;T;LADME-PK;DECREASED_TRANSPORT;;SLCO2B1
ESTRONE SULFATE;SLCO2B1;rs2306168;T;LADME-PK;DECREASED_TRANSPORT;;SLCO2B1
FLUOROURACIL;DPYD;rs548783838;T;LADME-PK;DECREASED_ACTIVITY;DRUG_ACCUMULATION;ENZIME:DPD
;CYP2B6;CYP2B6*1, CYP2B6*6;*1/*1;EFFICACY;INCREASED_ACTIVITY;;CYP2B6
BUPROPION;CYP2B6;CYP2B6*1, CYP2B6*6;*1/*1;EFFICACY;INCREASED_ACTIVITY;;CYP2B6
FLUOROURACIL;DPYD;rs140989814;G;LADME-PK;DECREASED_ACTIVITY;DRUG_ACCUMULATION;ENZIME:DPD
MEPHENYTOIN, OMEPRAZOLE;CYP2C19;CYP2C19*1, CYP2C19*8;*8;LADME-PK;DECREASED_ACTIVITY;DRUG_ACCUMULATION;ENZYME:CYP2C19
MEPHENYTOIN;CYP2C19;CYP2C19*1, CYP2C19*13;*13;LADME-PK;DECREASED_ACTIVITY;DRUG_ACCUMULATION;ENZYME:CYP2C19
BLONANSERIN;CYP3A4;CYP3A4*1, CYP3A4*29;*29;LADME-PK;INCREASED_ACTIVITY;;CYP3A4
TESTOSTERONE;CYP3A4;rs35599367;AG;LADME-PK;DECREASED_ACTIVITY;DRUG_ACCUMULATION;CYP3A4
ACALABRUTINIB;CYP3A4;CYP3A4*1, CYP3A4*2, CYP3A4*3, CYP3A4*11, CYP3A4*29, CYP3A4*33;*2 + *3 + *11 + *29 + *33;LADME-PK;INCREASED_CATALYTIC_ACTIVITY;;CYP3A4
ACALABRUTINIB;CYP3A4;CYP3A4*1, CYP3A4*9, CYP3A4*14, CYP3A4*16, CYP3A4*19, CYP3A4*23, CYP3A4*24, CYP3A4*28, CYP3A4*32;*9 + *14 + *16 + *19 + *23 + *24 + *28 + *32;LADME-PK;DECREASED_CATALYTIC_ACTIVITY;INCREASED_RISK;CYP3A4
VANDETANIB;CYP3A4;CYP3A4*1, CYP3A4*2, CYP3A4*3, CYP3A4*9, CYP3A4*15, CYP3A4*16, CYP3A4*29, CYP3A4*32, CYP3A4*33;*2 + *3 + *9 + *15 + *16 + *29 + *32 + *33;LADME-PK;INCREASED_CLEARANCE;LIKELIHOOD_THERAPEUTIC_SUCCESS;CYP3A4
MEPHENYTOIN, OMEPRAZOLE;CYP2C19;CYP2C19*1, CYP2C19*10;*10;LADME-PK;DECREASED_ACTIVITY;DRUG_ACCUMULATION;ENZYME:CYP2C19
FLUOROURACIL;DPYD;rs1801266;A;LADME-PK;DECREASED_ACTIVITY;DRUG_ACCUMULATION;ENZIME:DPD
DEXTROMETHORPHAN;SEPTIN3, WBP2NL;rs1062753;G;LADME-PK;INCREASED_ENZYME_ACTIVITY;;CYP2D6
BUMETANIDE;SLC17A3;rs34376145;A;LADME-PK;DECREASED_TRANSPORT;;SLC17A3
BUMETANIDE;SLC17A3;rs34902660;A;LADME-PK;DECREASED_TRANSPORT;;SLC17A3
BUMETANIDE;SLC17A3;rs11966370;A;LADME-PK;DECREASED_TRANSPORT;;SLC17A3
BUMETANIDE;SLC17A3;rs56027330;T;LADME-PK;DECREASED_TRANSPORT;;SLC17A3
OMEPRAZOLE;CYP2C19;rs148247410;G;LADME-PK;DECREASED_ACTIVITY;DRUG_ACCUMULATION;ENZYME:CYP2C19
FLUOROURACIL;DPYD;rs528152707;A;LADME-PK;DECREASED_ACTIVITY;DRUG_ACCUMULATION;ENZIME:DPD
FLUOROURACIL;DPYD;rs570122671;A;LADME-PK;DECREASED_ACTIVITY;DRUG_ACCUMULATION;ENZIME:DPD
FLUOROURACIL;DPYD;rs201268750;T;LADME-PK;DECREASED_ACTIVITY;DRUG_ACCUMULATION;ENZIME:DPD
FLUOROURACIL;DPYD;rs527580106;C;LADME-PK;DECREASED_ACTIVITY;DRUG_ACCUMULATION;ENZIME:DPD
FLUOROURACIL;DPYD;rs55886062;C;LADME-PK;DECREASED_ACTIVITY;DRUG_ACCUMULATION;ENZIME:DPD
MEPHENYTOIN, OMEPRAZOLE;CYP2C19;rs550527959;T;LADME-PK;DECREASED_ACTIVITY;DRUG_ACCUMULATION;ENZYME:CYP2C19
FLUOROURACIL;DPYD;rs538703919;A;LADME-PK;DECREASED_ACTIVITY;DRUG_ACCUMULATION;ENZIME:DPD
IBUPROFEN;CYP3A4;CYP3A4*1, CYP3A4*4, CYP3A4*5, CYP3A4*18, CYP3A4*23, CYP3A4*28, CYP3A4*29, CYP3A4*31, CYP3A4*32, CYP3A4*33, CYP3A4*34;*4 + *5 + *18 + *23 +  *32 + *34 + *28 + *29 + *31 + *33;OTHER;DECREASED_CLEARANCE;;CYP3A4
BLONANSERIN;CYP3A4;CYP3A4*1, CYP3A4*20;*20;LADME-PK;DECREASED_ACTIVITY;DRUG_ACCUMULATION;CYP3A4
MEPHENYTOIN, OMEPRAZOLE;CYP2C19;rs763625282;A;LADME-PK;DECREASED_ACTIVITY;DRUG_ACCUMULATION;ENZYME:CYP2C19
BLONANSERIN;CYP3A4;CYP3A4*1, CYP3A4*4, CYP3A4*5, CYP3A4*7, CYP3A4*8, CYP3A4*9, CYP3A4*10, CYP3A4*12, CYP3A4*13, CYP3A4*14, CYP3A4*16, CYP3A4*17, CYP3A4*18, CYP3A4*23, CYP3A4*24, CYP3A4*28, CYP3A4*31, CYP3A4*33, CYP3A4*34;*4 + *5 + *7 + *8 + *9 + *10 + *12 + *13 + *14 + *16 + *17 + *18 + *23 + *24 + *28 + *31 + *33 + *34;LADME-PK;DECREASED_ACTIVITY;DRUG_ACCUMULATION;CYP3A4
REGORAFENIB;CYP3A4;CYP3A4*1, CYP3A4*20;*20;LADME-PK;DECREASED_CATALYTIC_ACTIVITY;INCREASED_RISK;CYP3A4
FLUOROURACIL;DPYD;rs72549307;C;LADME-PK;DECREASED_ACTIVITY;DRUG_ACCUMULATION;ENZIME:DPD
OMEPRAZOLE;CYP2C19;rs1431015009;T;LADME-PK;DECREASED_ACTIVITY;DRUG_ACCUMULATION;ENZYME:CYP2C19
BUFURALOL;CYP2D6;rs1058171;T;LADME-PK;DECREASED_ACTIVITY;DRUG_ACCUMULATION;CYP2D6
DICLOFENAC, LOSARTAN, TOLBUTAMIDE;CYP2C9;CYP2C9*72;*72;LADME-PK;DECREASED_ENZYME_ACTIVITY;DRUG_ACCUMULATION;ENZYME:CYP2C9
SUMATRIPTAN;HTR1B;rs130060;C;LADME-PD;INCREASED_CONCENTRATIONS;;AMPc
BUFURALOL;CYP2D6;rs1230912765;A;LADME-PK;DECREASED_ACTIVITY;DRUG_ACCUMULATION;CYP2D6
PURINE ANALOGUES;PACSIN2;rs2413739;C;OTHER, LADME-PK;INCREASED_ACTIVITY;;TPMT
L-PHENYLALANINE;PAH;rs76394784;A;LADME-PK;DECREASED_ACTIVITY;DRUG_ACCUMULATION;PAH
CARBOCISTEINE;PAH;rs62516101;T;LADME-PK;DECREASED_ACTIVITY;DRUG_ACCUMULATION;PAH
CARBOCISTEINE;PAH;rs75193786;G;LADME-PK;DECREASED_ACTIVITY;DRUG_ACCUMULATION;PAH
DICLOFENAC, LOSARTAN, TOLBUTAMIDE;CYP2C9;CYP2C9*3;*3;LADME-PK;DECREASED_ENZYME_ACTIVITY;DRUG_ACCUMULATION;ENZYME:CYP2C9
LOSARTAN;CYP2C9;CYP2C9*75;*75;LADME-PK;DECREASED_ENZYME_ACTIVITY;DRUG_ACCUMULATION;ENZYME:CYP2C9
L-PHENYLALANINE;PAH;rs62516101;T;LADME-PK;DECREASED_ACTIVITY;DRUG_ACCUMULATION;PAH
CARBOCISTEINE;PAH;rs5030860;C;LADME-PK;DECREASED_ACTIVITY;DRUG_ACCUMULATION;PAH
L-PHENYLALANINE;PAH;rs5030849;T;LADME-PK;DECREASED_ACTIVITY;DRUG_ACCUMULATION;PAH
CARBOCISTEINE;PAH;rs76394784;A;LADME-PK;DECREASED_ACTIVITY;DRUG_ACCUMULATION;PAH
DICLOFENAC;CYP2C9;CYP2C9*3;*3;LADME-PK;DECREASED_CATALYTIC_ACTIVITY;INCREASED_RISK;ENZYME:CYP2C9
WARFARIN;CYP2C9;CYP2C9*60;*60;LADME-PK;DECREASED_ENZYME_ACTIVITY;DRUG_ACCUMULATION;ENZYME:CYP2C9
DICLOFENAC;CYP2C9;CYP2C9*37;*37;LADME-PK;DECREASED_CATALYTIC_ACTIVITY;INCREASED_RISK;ENZYME:CYP2C9
DICLOFENAC;CYP2C9;CYP2C9*46;*46;LADME-PK;DECREASED_CATALYTIC_ACTIVITY;INCREASED_RISK;ENZYME:CYP2C9
CARBOCISTEINE;PAH;rs5030849;T;LADME-PK;DECREASED_ACTIVITY;DRUG_ACCUMULATION;PAH
L-PHENYLALANINE;PAH;rs5030860;C;LADME-PK;DECREASED_ACTIVITY;DRUG_ACCUMULATION;PAH
DICLOFENAC;CYP2C9;CYP2C9*54;*54;LADME-PK;INCREASED_CATALYTIC_ACTIVITY;;ENZYME:CYP2C9
DICLOFENAC, LOSARTAN, TOLBUTAMIDE;CYP2C9;CYP2C9*74;*74;LADME-PK;DECREASED_ENZYME_ACTIVITY;DRUG_ACCUMULATION;ENZYME:CYP2C9
TOLBUTAMIDE;CYP2C9;rs9332239;T;LADME-PK;DECREASED_CATALYTIC_ACTIVITY;INCREASED_RISK;ENZYME:CYP2C9
BUFURALOL;CYP2D6;CYP2D6*1, CYP2D6*49, CYP2D6*55;*49 + *55;LADME-PK;DECREASED_ENZYME_ACTIVITY;;CYP2D6
TOLTERODINE;CYP2D6;CYP2D6*92, CYP2D6*96;*92 + *96;LADME-PK;DECREASED_ACTIVITY;DRUG_ACCUMULATION;CYP2D6
GEFITINIB;CYP2D6;CYP2D6*92, CYP2D6*96;*92 + *96;LADME-PK;DECREASED_CATALYTIC_ACTIVITY;INCREASED_RISK;CYP2D6
DEXTROMETHORPHAN;CYP2D6;CYP2D6*1, CYP2D6*10, CYP2D6*18, CYP2D6*36, CYP2D6*47, CYP2D6*49, CYP2D6*50, CYP2D6*51, CYP2D6*54, CYP2D6*55, CYP2D6*114;*10 + *18 + *36 + *47 + *49 + *50 + *51 + *54 + *55 + *114;LADME-PK;DECREASED_ENZYME_ACTIVITY;;CYP2D6
BUFURALOL;CYP2D6;CYP2D6*1, CYP2D6*18;*18;LADME-PK;DECREASED_ENZYME_ACTIVITY;;CYP2D6
HYDRALAZINE;NAT2;NAT2*4, NAT2*5, NAT2*6, NAT2*7;*4/*5 + *4/*6;OTHER;INCREASED_ACTIVITY;;NAT2
HYDRALAZINE;NAT2;NAT2*4, NAT2*5, NAT2*6;*4/*4;OTHER;INCREASED_ACTIVITY;;NAT2
BUFURALOL;CYP2D6;CYP2D6*1, CYP2D6*36;*36;LADME-PK;DECREASED_ENZYME_ACTIVITY;;CYP2D6
DICLOFENAC, LOSARTAN;CYP2C9;CYP2C9*73;*73;LADME-PK;DECREASED_ENZYME_ACTIVITY;DRUG_ACCUMULATION;ENZYME:CYP2C9
BUFURALOL;CYP2D6;CYP2D6*1, CYP2D6*36;*36;LADME-PK;DECREASED_ENZYME_ACTIVITY;;CYP2D6
FLUOXETINE;CYP2D6;CYP2D6*2, CYP2D6*10, CYP2D6*87, CYP2D6*92, CYP2D6*93, CYP2D6*96;*10 + *92 + *93 + *96 + *87 + *2;LADME-PK;DECREASED_CATALYTIC_ACTIVITY;INCREASED_RISK;CYP2D6
BUFURALOL;CYP2D6;CYP2D6*1, CYP2D6*2, CYP2D6*10, CYP2D6*89, CYP2D6*92, CYP2D6*93, CYP2D6*96;*2 + *10 + *89 + *92 + *93 + *96;LADME-PK;DECREASED_CATALYTIC_ACTIVITY;INCREASED_RISK;CYP2D6
TOLBUTAMIDE;CYP2C9;CYP2C9*60;*60;LADME-PK;DECREASED_ENZYME_ACTIVITY;DRUG_ACCUMULATION;ENZYME:CYP2C9
TOLBUTAMIDE;CYP2C9;CYP2C9*3;*3;LADME-PK;DECREASED_ENZYME_ACTIVITY;DRUG_ACCUMULATION;ENZYME:CYP2C9
DICLOFENAC;CYP2C9;CYP2C9*3;*3;LADME-PK;DECREASED_ENZYME_ACTIVITY;DRUG_ACCUMULATION;ENZYME:CYP2C9
DICLOFENAC;CYP2C9;CYP2C9*60;*60;LADME-PK;DECREASED_ENZYME_ACTIVITY;DRUG_ACCUMULATION;ENZYME:CYP2C9
DEXTROMETHORPHAN;CYP2D6;CYP2D6*1, CYP2D6*10;*10;LADME-PK;DECREASED_CATALYTIC_ACTIVITY;INCREASED_RISK;CYP2D6
WARFARIN;CYP2C9;CYP2C9*3;*3;LADME-PK;DECREASED_ENZYME_ACTIVITY;DRUG_ACCUMULATION;ENZYME:CYP2C9
BUFURALOL;CYP2D6;CYP2D6*1, CYP2D6*50;*50;LADME-PK;DECREASED_ENZYME_ACTIVITY;;CYP2D6
DICLOFENAC;CYP2C9;CYP2C9*44;*44;LADME-PK;DECREASED_CATALYTIC_ACTIVITY;INCREASED_RISK;ENZYME:CYP2C9
DICLOFENAC;CYP2C9;CYP2C9*42;*42;LADME-PK;DECREASED_CATALYTIC_ACTIVITY;INCREASED_RISK;ENZYME:CYP2C9
DICLOFENAC;CYP2C9;CYP2C9*40;*40;LADME-PK;INCREASED_CATALYTIC_ACTIVITY;;ENZYME:CYP2C9
MEPHENYTOIN, OMEPRAZOLE;CYP2C19;rs200346442;A;LADME-PK;DECREASED_ACTIVITY;DRUG_ACCUMULATION;ENZYME:CYP2C19
MEPHENYTOIN, OMEPRAZOLE;CYP2C19;rs200150287;G;LADME-PK;DECREASED_ACTIVITY;DRUG_ACCUMULATION;ENZYME:CYP2C19
MEPHENYTOIN, OMEPRAZOLE;CYP2C19;rs150152656;T;LADME-PK;DECREASED_ACTIVITY;DRUG_ACCUMULATION;ENZYME:CYP2C19
BUPROPION;POR;rs2868177;AA;OTHER, LADME-PK;DECREASED_ENZYME_ACTIVITY;;CYP2B6
BUPROPION;POR;rs2868177;GG;OTHER, LADME-PK;INCREASED_ACTIVITY;;CYP2B6
BUFURALOL;CYP2D6;CYP2D6*1, CYP2D6*51;*51;LADME-PK;DECREASED_ENZYME_ACTIVITY;;CYP2D6
MEPHENYTOIN;CYP2C19;CYP2C19*1, CYP2C19*32;*32;LADME-PK;DECREASED_ACTIVITY;DRUG_ACCUMULATION;ENZYME:CYP2C19
MEPHENYTOIN, OMEPRAZOLE;CYP2C19;CYP2C19*1, CYP2C19*29, CYP2C19*30, CYP2C19*31, CYP2C19*33;*29 + *30 + *31 + *33;LADME-PK;DECREASED_ACTIVITY;DRUG_ACCUMULATION;ENZYME:CYP2C19
;POR;rs2868177;AA;OTHER, LADME-PK;DECREASED_ACTIVITY;;CYP2B6
CLOPIDOGREL;CYP2C19;CYP2C19*1, CYP2C19*10;*10;LADME-PK;DECREASED_CATALYTIC_ACTIVITY;INCREASED_RISK;ENZYME:CYP2C19
OMEPRAZOLE;CYP2C19;rs140278421;A;LADME-PK;DECREASED_ACTIVITY;DRUG_ACCUMULATION;ENZYME:CYP2C19
OMEPRAZOLE;CYP2C19;rs1361528097;G;LADME-PK;DECREASED_ACTIVITY;DRUG_ACCUMULATION;ENZYME:CYP2C19
MEPHENYTOIN, OMEPRAZOLE;CYP2C19;CYP2C19*1, CYP2C19*3;*3;LADME-PK;DECREASED_ACTIVITY;DRUG_ACCUMULATION;ENZYME:CYP2C19
FLUOROURACIL;DPYD;rs536577604;C;LADME-PK;DECREASED_ACTIVITY;DRUG_ACCUMULATION;ENZIME:DPD
DEBRISOQUINE;CYP2D6;CYP2D6*1, CYP2D6*10;*10;LADME-PK;DECREASED_CATALYTIC_ACTIVITY;INCREASED_RISK;CYP2D6
MEPHENYTOIN, OMEPRAZOLE;CYP2C19;rs1267723490;C;LADME-PK;DECREASED_ACTIVITY;DRUG_ACCUMULATION;ENZYME:CYP2C19
BUFURALOL;CYP2D6;CYP2D6*1, CYP2D6*54;*54;LADME-PK;DECREASED_ENZYME_ACTIVITY;;CYP2D6
BUFURALOL, DEBRISOQUINE;CYP2D6;CYP2D6*1, CYP2D6*29;*29;LADME-PK;DECREASED_CATALYTIC_ACTIVITY;INCREASED_RISK;CYP2D6
BUFURALOL;CYP2D6;CYP2D6*1, CYP2D6*47;*47;LADME-PK;DECREASED_ENZYME_ACTIVITY;;CYP2D6
MEPHENYTOIN, OMEPRAZOLE;CYP2C19;rs764137538;T;LADME-PK;DECREASED_ACTIVITY;DRUG_ACCUMULATION;ENZYME:CYP2C19
IBUPROFEN;CYP2C19;CYP2C19*1, CYP2C19*3, CYP2C19*35;*3 + *35;OTHER;DECREASED_CATALYTIC_ACTIVITY;INCREASED_RISK;ENZYME:CYP2C19
IBUPROFEN;CYP2C19;CYP2C19*1, CYP2C19*30, CYP2C19*31, CYP2C19*32, CYP2C19*33;*33 + *30 + *31 + *32;OTHER;DECREASED_CATALYTIC_ACTIVITY;INCREASED_RISK;ENZYME:CYP2C19
DEXTROMETHORPHAN;PHETA2, SMDT1;rs1807493;G;LADME-PK;INCREASED_ENZYME_ACTIVITY;;CYP2D6
BUFURALOL;CYP2D6;CYP2D6*1, CYP2D6*10;*10;LADME-PK;DECREASED_ENZYME_ACTIVITY;;CYP2D6
DICLOFENAC;CYP2C9;CYP2C9*52;*52;LADME-PK;DECREASED_CATALYTIC_ACTIVITY;INCREASED_RISK;ENZYME:CYP2C9
DICLOFENAC;CYP2C9;CYP2C9*43;*43;LADME-PK;DECREASED_CATALYTIC_ACTIVITY;INCREASED_RISK;ENZYME:CYP2C9
DICLOFENAC;CYP2C9;CYP2C9*45;*45;LADME-PK;DECREASED_CATALYTIC_ACTIVITY;INCREASED_RISK;ENZYME:CYP2C9
DICLOFENAC;CYP2C9;CYP2C9*36;*36;LADME-PK;DECREASED_CATALYTIC_ACTIVITY;INCREASED_RISK;ENZYME:CYP2C9
DICLOFENAC;CYP2C9;CYP2C9*55;*55;LADME-PK;DECREASED_CATALYTIC_ACTIVITY;INCREASED_RISK;ENZYME:CYP2C9
DICLOFENAC;CYP2C9;CYP2C9*39;*39;LADME-PK;DECREASED_CATALYTIC_ACTIVITY;INCREASED_RISK;ENZYME:CYP2C9
DICLOFENAC;CYP2C9;CYP2C9*50;*50;LADME-PK;DECREASED_CATALYTIC_ACTIVITY;INCREASED_RISK;ENZYME:CYP2C9
DICLOFENAC;CYP2C9;CYP2C9*47;*47;LADME-PK;DECREASED_CATALYTIC_ACTIVITY;INCREASED_RISK;ENZYME:CYP2C9
DICLOFENAC;CYP2C9;CYP2C9*53;*53;LADME-PK;DECREASED_CATALYTIC_ACTIVITY;INCREASED_RISK;ENZYME:CYP2C9
DICLOFENAC;CYP2C9;CYP2C9*38;*38;LADME-PK;DECREASED_CATALYTIC_ACTIVITY;INCREASED_RISK;ENZYME:CYP2C9
DICLOFENAC;CYP2C9;CYP2C9*48;*48;LADME-PK;DECREASED_CATALYTIC_ACTIVITY;INCREASED_RISK;ENZYME:CYP2C9
MEPHENYTOIN, OMEPRAZOLE;CYP2C19;rs1463550071;T;LADME-PK;DECREASED_ACTIVITY;DRUG_ACCUMULATION;ENZYME:CYP2C19
MEPHENYTOIN, OMEPRAZOLE;CYP2C19;rs1349931378;A;LADME-PK;DECREASED_ACTIVITY;DRUG_ACCUMULATION;ENZYME:CYP2C19
DEBRISOQUINE;CYP2D6;CYP2D6*1, CYP2D6*75;*75;LADME-PK;DECREASED_CATALYTIC_ACTIVITY;INCREASED_RISK;CYP2D6
OMEPRAZOLE;CYP2C19;rs1393133490;T;LADME-PK;DECREASED_ACTIVITY;DRUG_ACCUMULATION;ENZYME:CYP2C19
OMEPRAZOLE;CYP2C19;rs1466428833;G;LADME-PK;DECREASED_ACTIVITY;DRUG_ACCUMULATION;ENZYME:CYP2C19
MEPHENYTOIN, OMEPRAZOLE;CYP2C19;rs749678783;C;LADME-PK;DECREASED_ACTIVITY;DRUG_ACCUMULATION;ENZYME:CYP2C19
IBRUTINIB;CYP3A4;CYP3A4*1, CYP3A4*17, CYP3A4*24;*17 + *24;LADME-PK;DECREASED_CATALYTIC_ACTIVITY;INCREASED_RISK;CYP3A4
EFAVIRENZ;CYP2B6;rs58871670;A;LADME-PK;DECREASED_CATALYTIC_ACTIVITY;INCREASED_RISK;CYP2B6
FLUOROURACIL;DPYD;rs72547601;C;LADME-PK;DECREASED_ACTIVITY;DRUG_ACCUMULATION;ENZIME:DPD
BUPROPION;CYP2B6;rs201500445;C;LADME-PK;DECREASED_CATALYTIC_ACTIVITY;INCREASED_RISK;CYP2B6
MERCAPTOPURINE;TPMT;TPMT*1, TPMT*3A, TPMT*3B;*1/*3A + *1/*3B;LADME-PK;DECREASED_ENZYME_ACTIVITY;;TPMT
FLUOROURACIL;DPYD;rs188052243;C;LADME-PK;DECREASED_CATALYTIC_ACTIVITY;INCREASED_RISK;DPYD
MERCAPTOPURINE;TPMT;TPMT*1, TPMT*3A, TPMT*3C;*1/*3A;LADME-PK;DECREASED_ENZYME_ACTIVITY;;TPMT
MERCAPTOPURINE;TPMT;TPMT*1, TPMT*3C;*1/*3C;LADME-PK;DECREASED_ENZYME_ACTIVITY;;TPMT
DAUNORUBICIN, DOXORUBICIN;AKR7A2;rs1043657;T;LADME-PK;DECREASED_ENZYME_ACTIVITY;;AKR7A2
DAUNORUBICIN;AKR1C4;rs17134592;G;LADME-PK;DECREASED_ENZYME_ACTIVITY;;AKR1C4
MERCAPTOPURINE;TPMT;TPMT*1, TPMT*3A, TPMT*3C;*1/*1;LADME-PK;INCREASED_ENZYME_ACTIVITY;;TPMT
MERCAPTOPURINE;TPMT;rs3931660;AT;LADME-PK;DECREASED_ENZYME_ACTIVITY;;TPMT
MERCAPTOPURINE;TPMT;rs1142345;CT;LADME-PK;DECREASED_ENZYME_ACTIVITY;;TPMT
DAUNORUBICIN;AKR1C3;rs4987102;A;LADME-PK;DECREASED_ENZYME_ACTIVITY;;AKR1C3
DAUNORUBICIN, DOXORUBICIN;AKR1C3;rs35575889;T;LADME-PK;DECREASED_ENZYME_ACTIVITY;;AKR1C3
DAUNORUBICIN, DOXORUBICIN;AKR1C3;rs34186955;T;LADME-PK;DECREASED_ENZYME_ACTIVITY;;AKR1C3
;TPMT;TPMT*1, TPMT*2, TPMT*3A, TPMT*5, TPMT*12, TPMT*14, TPMT*18, TPMT*22;*2 + *3A + *5 + *12 + *14 + *18 + *22;LADME-PK;DECREASED_EXPRESSION;;TPMT
FLUOROURACIL;DPYD;rs72549306;A;LADME-PK;DECREASED_CATALYTIC_ACTIVITY;INCREASED_RISK;DPYD
SN-38;UGT1A1;UGT1A1*1, UGT1A1*28, UGT1A1*37;*1/*28 + *28/*28 + *1/*37;LADME-PK;DECREASED_ENZYME_ACTIVITY;;UGT1A1
SN-38;UGT1A1;rs4148323;A;LADME-PK;DECREASED_ENZYME_ACTIVITY;;UGT1A1
FLUOROURACIL;DPYD;rs137999090;T;LADME-PK;DECREASED_ACTIVITY;DRUG_ACCUMULATION;ENZIME:DPD
FLUOROURACIL;DPYD;rs145773863;T;LADME-PK;DECREASED_ACTIVITY;DRUG_ACCUMULATION;ENZIME:DPD
17BETA-ESTRADIOL GLUCURONIDE;ABCC4;rs200858900;T;LADME-PK;DECREASED_CATALYTIC_ACTIVITY;INCREASED_RISK;ABCC4
MERCAPTOPURINE;TPMT;TPMT*1, TPMT*2, TPMT*3A, TPMT*3C;*1/*2 + *1/*3A + *1/*3C;LADME-PK;DECREASED_ACTIVITY;DRUG_ACCUMULATION;TPMT
FLUOROURACIL;DPYD;rs59086055;A;LADME-PK;DECREASED_ACTIVITY;DRUG_ACCUMULATION;ENZIME:DPD
MERCAPTOPURINE;TPMT;TPMT*1, TPMT*3B, TPMT*3C;*3B/*3C;LADME-PK;DECREASED_ENZYME_ACTIVITY;;TPMT
PURINE ANALOGUES;TPMT;rs1142345;CT;OTHER, LADME-PK;DECREASED_ACTIVITY;;TPMT
ELEXACAFTOR, TEZACAFTOR;CFTR;rs1792306355;T;EFFICACY;INCREASED_ACTIVITY;;CFTR
ELEXACAFTOR / TEZACAFTOR / IVACAFTOR;CFTR;rs186089140;CT;LADME-PD;INCREASED_ACTIVITY;;CFTR
ELEXACAFTOR / TEZACAFTOR / IVACAFTOR, IVACAFTOR / TEZACAFTOR;CFTR;rs35516286;A;LADME-PD;INCREASED_ACTIVITY;;CFTR
CLOPIDOGREL, ENALAPRIL, SACUBITRIL;CES1;rs143718310;G;LADME-PK;DECREASED_METABOLISM;;
ENALAPRIL;CES1;rs202121317;C;LADME-PK;DECREASED_ENZYME_ACTIVITY;;
REMIMAZOLAM;CES1;rs2307240;T;LADME-PK;INCREASED_CATALYTIC_ACTIVITY;;CES1
CLOPIDOGREL;CES1;rs202001817;A;LADME-PK;DECREASED_ENZYME_ACTIVITY;;
REMIMAZOLAM;CES1;rs71647871;T;LADME-PK;DECREASED_CATALYTIC_ACTIVITY;INCREASED_RISK;CES1
REMIMAZOLAM;CES1;rs151291296;C;LADME-PK;DECREASED_CATALYTIC_ACTIVITY;INCREASED_RISK;CES1
CLOPIDOGREL, ENALAPRIL, SACUBITRIL;CES1;rs151291296;C;LADME-PK;DECREASED_ENZYME_ACTIVITY;;
CLOPIDOGREL, ENALAPRIL, SACUBITRIL;CES1;rs146456965;A;LADME-PK;DECREASED_METABOLISM;;
REMIMAZOLAM;CES1;rs143718310;G;LADME-PK;DECREASED_CATALYTIC_ACTIVITY;INCREASED_RISK;CES1
CLOPIDOGREL, ENALAPRIL, SACUBITRIL;CES1;rs200707504;C;LADME-PK;DECREASED_ENZYME_ACTIVITY;;
ENALAPRIL;CES1;rs2307243;T;LADME-PK;DECREASED_ENZYME_ACTIVITY;;
REMIMAZOLAM;CES1;rs200707504;C;LADME-PK;DECREASED_CATALYTIC_ACTIVITY;INCREASED_RISK;CES1
BUPROPION;CYP2B6;rs58871670;A;LADME-PK;DECREASED_CATALYTIC_ACTIVITY;INCREASED_RISK;CYP2B6
FLUOROURACIL;DPYD;rs755692084;G;LADME-PK;DECREASED_ACTIVITY;DRUG_ACCUMULATION;ENZIME:DPD
MERCAPTOPURINE;TPMT;TPMT*1, TPMT*2, TPMT*3A, TPMT*3B, TPMT*3C, TPMT*5, TPMT*6, TPMT*8, TPMT*10, TPMT*11, TPMT*12, TPMT*13;*2 + *3A + *3B + *3C + *5 + *6 + *8 + *10 + *11 + *12 + *13;LADME-PK;DECREASED_ENZYME_ACTIVITY;;TPMT
THIOGUANINE;TPMT;TPMT*1, TPMT*2, TPMT*3A, TPMT*3B, TPMT*3C, TPMT*5, TPMT*6, TPMT*7, TPMT*9, TPMT*10, TPMT*12, TPMT*14, TPMT*17, TPMT*18, TPMT*19, TPMT*20, TPMT*21, TPMT*22, TPMT*23, TPMT*30;*2 + *3A + *3B + *3C + *5 + *6 + *7 + *9 + *10 + *12 + *14 + *17 + *18 + *19 + *20 + *21 + *22 + *23 + *30;LADME-PK;DECREASED_ENZYME_ACTIVITY;;TPMT
MERCAPTOPURINE;TPMT;TPMT*1, TPMT*3A, TPMT*3B, TPMT*3C;*1/*3A + *1/*3B + *1/*3C;LADME-PK;DECREASED_ENZYME_ACTIVITY;;TPMT
ELEXACAFTOR, TEZACAFTOR;CFTR;rs758900656;T;EFFICACY;INCREASED_ACTIVITY;;CFTR
17BETA-ESTRADIOL GLUCURONIDE;ABCC4;rs11568681;T;LADME-PK;INCREASED_CATALYTIC_ACTIVITY;;ABCC4
FLUOROURACIL;DPYD;rs183385770;T;LADME-PK;DECREASED_ACTIVITY;DRUG_ACCUMULATION;ENZIME:DPD
ESLICARBAZEPINE ACETATE;AADAC;rs35084477;A;LADME-PK;INCREASED_CATALYTIC_ACTIVITY;;AADAC
ESLICARBAZEPINE ACETATE;AADAC;rs1803155;A;LADME-PK;INCREASED_CATALYTIC_ACTIVITY;;AADAC
ESLICARBAZEPINE ACETATE;AADAC;rs61733692;C;LADME-PK;DECREASED_CATALYTIC_ACTIVITY;INCREASED_RISK;AADAC
FLUOROURACIL;DPYD;rs114096998;T;LADME-PK;INCREASED_ACTIVITY;;DPYD
FLUOROURACIL;DPYD;rs60139309;C;LADME-PK;INCREASED_ACTIVITY;;DPYD
FLUOROURACIL;DPYD;rs143986398;C;LADME-PK;DECREASED_ACTIVITY;DRUG_ACCUMULATION;ENZIME:DPD
SN-38;UGT1A9;rs11692021;C;LADME-PK;DECREASED_ENZYME_ACTIVITY;;UGT1A1
SN-38;UGT1A9;rs72551344;G;LADME-PK;DECREASED_ENZYME_ACTIVITY;;UGT1A1
SN-38;UGT1A9;rs34993780;G;LADME-PK;DECREASED_ENZYME_ACTIVITY;;UGT1A1
FLUOROURACIL;DPYD;rs72549308;G;LADME-PK;DECREASED_ACTIVITY;DRUG_ACCUMULATION;ENZIME:DPD
FLUOROURACIL;DPYD;rs1184321568;del;LADME-PK;DECREASED_CATALYTIC_ACTIVITY;INCREASED_RISK;DPYD
FLUOROURACIL;DPYD;rs143879757;A;LADME-PK;DECREASED_CATALYTIC_ACTIVITY;INCREASED_RISK;DPYD
FLUOROURACIL;DPYD;rs59086055;A;LADME-PK;DECREASED_CATALYTIC_ACTIVITY;INCREASED_RISK;DPYD
FLUOROURACIL;DPYD;rs148994843;T;LADME-PK;DECREASED_CATALYTIC_ACTIVITY;INCREASED_RISK;DPYD
DEXTROMETHORPHAN;;rs729559;GG;LADME-PK;INCREASED_ENZYME_ACTIVITY;;CYP2D6
FLUOROURACIL;DPYD;rs748620513;G;LADME-PK;DECREASED_CATALYTIC_ACTIVITY;INCREASED_RISK;DPYD
DEXTROMETHORPHAN;;rs4073010;TT;LADME-PK;INCREASED_ENZYME_ACTIVITY;;CYP2D6
FLUOROURACIL;DPYD;rs72549304;A;LADME-PK;DECREASED_ACTIVITY;DRUG_ACCUMULATION;ENZIME:DPD
FLUOROURACIL;DPYD;rs200687447;T;LADME-PK;INCREASED_ACTIVITY;;DPYD
ESLICARBAZEPINE ACETATE;AADAC;rs144650170;G;LADME-PK;INCREASED_CATALYTIC_ACTIVITY;;AADAC
FLUOROURACIL;DPYD;rs146356975;C;LADME-PK;DECREASED_ACTIVITY;DRUG_ACCUMULATION;ENZIME:DPD
ESLICARBAZEPINE ACETATE;AADAC;rs140197497;G;LADME-PK;INCREASED_CATALYTIC_ACTIVITY;;AADAC
FLUOROURACIL;DPYD;rs2297595;C;LADME-PK;INCREASED_ACTIVITY;;DPYD
FLUOROURACIL;DPYD;rs183105782;G;LADME-PK;DECREASED_ACTIVITY;DRUG_ACCUMULATION;ENZIME:DPD
FLUOROURACIL;DPYD;rs190577302;C;LADME-PK;DECREASED_ACTIVITY;DRUG_ACCUMULATION;ENZIME:DPD
17BETA-ESTRADIOL GLUCURONIDE;ABCC4;rs11568644;A;LADME-PK;DECREASED_CATALYTIC_ACTIVITY;INCREASED_RISK;ABCC4
17BETA-ESTRADIOL GLUCURONIDE;ABCC4;rs142211148;T;LADME-PK;INCREASED_CATALYTIC_ACTIVITY;;ABCC4
FLUOROURACIL;DPYD;rs186169810;C;LADME-PK;DECREASED_ACTIVITY;DRUG_ACCUMULATION;ENZIME:DPD
FLUOROURACIL;DPYD;rs143154602;A;LADME-PK;DECREASED_ACTIVITY;DRUG_ACCUMULATION;ENZIME:DPD
FLUOROURACIL;DPYD;rs368146607;G;LADME-PK;DECREASED_ACTIVITY;DRUG_ACCUMULATION;ENZIME:DPD
FLUOROURACIL;DPYD;rs371258350;T;LADME-PK;DECREASED_ACTIVITY;DRUG_ACCUMULATION;ENZIME:DPD
FLUOROURACIL;DPYD;rs575853463;T;LADME-PK;DECREASED_ACTIVITY;DRUG_ACCUMULATION;ENZIME:DPD
FLUOROURACIL;DPYD;rs569661196;G;LADME-PK;DECREASED_ACTIVITY;DRUG_ACCUMULATION;ENZIME:DPD
FLUOROURACIL;DPYD;rs138616379;T;LADME-PK;DECREASED_ACTIVITY;DRUG_ACCUMULATION;ENZIME:DPD
AMISULPRIDE, ARIPIPRAZOLE, OLANZAPINE, RISPERIDONE;ABCB1;rs2229109;T;LADME-PK;DECREASED_TRANSPORT;;ABCB1
FLUOROURACIL;DPYD;rs115232898;C;LADME-PK;DECREASED_ACTIVITY;DRUG_ACCUMULATION;ENZIME:DPD
CLOZAPINE;UGT1A4;rs2011425;G;LADME-PK;INCREASED_CATALYTIC_ACTIVITY;;UGT1A4
FLUOROURACIL;DPYD;rs111858276;C;LADME-PK;DECREASED_ACTIVITY;DRUG_ACCUMULATION;ENZIME:DPD
ACETAMINOPHEN;UGT1A6;UGT1A6*1a, UGT1A6*2a;*2a;LADME-PK;INCREASED_ACTIVITY;;UGT1A6
FLUOROURACIL;DPYD;rs140039091;G;LADME-PK;DECREASED_ACTIVITY;DRUG_ACCUMULATION;ENZIME:DPD
FLUOROURACIL;DPYD;rs187713395;G;LADME-PK;DECREASED_ACTIVITY;DRUG_ACCUMULATION;ENZIME:DPD
SN-38;UGT1A9;rs35350960;A;LADME-PK;DECREASED_ENZYME_ACTIVITY;;UGT1A1
ESLICARBAZEPINE ACETATE;AADAC;rs186388618;T;LADME-PK;DECREASED_CATALYTIC_ACTIVITY;INCREASED_RISK;AADAC
ELEXACAFTOR, TEZACAFTOR;CFTR;rs397508139;A;EFFICACY;INCREASED_ACTIVITY;;CFTR
FLUOROURACIL;MIR27A;rs895819;C;LADME-PK;DECREASED_ENZYME_ACTIVITY;;DPYD
ELEXACAFTOR, TEZACAFTOR;CFTR;rs397508609;A;EFFICACY;INCREASED_ACTIVITY;;CFTR
FLUOROURACIL;DPYD;rs141044036;C;LADME-PK;DECREASED_ACTIVITY;DRUG_ACCUMULATION;ENZIME:DPD
ARACHIDONIC ACID;CYP4F2;rs753169154;G;LADME-PD;DECREASED_CATALYTIC_ACTIVITY;INCREASED_RISK;CYP4F2
EFAVIRENZ;CYP2B6;rs201500445;C;LADME-PK;DECREASED_CATALYTIC_ACTIVITY;INCREASED_RISK;CYP2B6
BUPROPION;CYP2B6;rs535039125;T;LADME-PK;DECREASED_CATALYTIC_ACTIVITY;INCREASED_RISK;CYP2B6
EFAVIRENZ;CYP2B6;rs117872433;A;LADME-PK;DECREASED_CATALYTIC_ACTIVITY;INCREASED_RISK;CYP2B6
BUPROPION;CYP2B6;rs200238771;A;LADME-PK;DECREASED_CATALYTIC_ACTIVITY;INCREASED_RISK;CYP2B6
ARACHIDONIC ACID;CYP4F2;rs114396708;A;LADME-PD;DECREASED_CATALYTIC_ACTIVITY;INCREASED_RISK;CYP4F2
COUMARIN, NICOTINE, TEGAFUR;CYP2A6;CYP2A6*1, CYP2A6*7, CYP2A6*19;*7 + *19;LADME-PK;DECREASED_CATALYTIC_ACTIVITY;INCREASED_RISK;CYP2A6
BUPROPION;CYP2B6;CYP2B6*47;*47;LADME-PK;DECREASED_CATALYTIC_ACTIVITY;INCREASED_RISK;CYP2B6
NICOTINE;CYP2A6;rs4803381;CC + CT;LADME-PK;INCREASED_ACTIVITY;;CYP2A6
EFAVIRENZ;CYP2B6;CYP2B6*47;*47;LADME-PK;DECREASED_CATALYTIC_ACTIVITY;INCREASED_RISK;CYP2B6
NICOTINE;CYP2A6;rs57837628;AG + GG;LADME-PK;INCREASED_ACTIVITY;;CYP2A6
COUMARIN, TEGAFUR;CYP2A6;CYP2A6*1, CYP2A6*18;*18;LADME-PK;DECREASED_CATALYTIC_ACTIVITY;INCREASED_RISK;CYP2A6
FLUOROURACIL;DPYD;rs67376798;A;LADME-PK;DECREASED_ACTIVITY;DRUG_ACCUMULATION;ENZIME:DPD
EFAVIRENZ;CYP2B6;CYP2B6*46;*46;LADME-PK;DECREASED_CATALYTIC_ACTIVITY;INCREASED_RISK;CYP2B6
NICOTINE;CYP2A6;rs72549435;C;LADME-PK;DECREASED_CATALYTIC_ACTIVITY;INCREASED_RISK;CYP2A6
EFAVIRENZ;CYP2B6;rs535039125;T;LADME-PK;DECREASED_CATALYTIC_ACTIVITY;INCREASED_RISK;CYP2B6
PREGNENOLONE;SULT2B1;rs746398875;T;LADME-PK;DECREASED_ENZYME_ACTIVITY;;SULT2B1
PREGNENOLONE;SULT2B1;rs762765702;A;LADME-PK;DECREASED_ENZYME_ACTIVITY;;SULT2B1
COUMARIN;CYP2A6;CYP2A6*4, CYP2A6*9;*4/*9;LADME-PK;DECREASED_ENZYME_ACTIVITY;;CYP2A6
BUPROPION;CYP2B6;rs374099483;A;LADME-PK;DECREASED_CATALYTIC_ACTIVITY;INCREASED_RISK;CYP2B6
BUPROPION;CYP2B6;rs764288403;A;LADME-PK;DECREASED_CATALYTIC_ACTIVITY;INCREASED_RISK;CYP2B6
BUPROPION;CYP2B6;CYP2B6*46;*46;LADME-PK;DECREASED_CATALYTIC_ACTIVITY;INCREASED_RISK;CYP2B6
EFAVIRENZ;CYP2B6;rs374099483;A;LADME-PK;DECREASED_CATALYTIC_ACTIVITY;INCREASED_RISK;CYP2B6
BUPROPION;CYP2B6;rs117872433;A;LADME-PK;DECREASED_CATALYTIC_ACTIVITY;INCREASED_RISK;CYP2B6
FLUOROURACIL;DPYD;rs112766203;A;LADME-PK;DECREASED_ACTIVITY;DRUG_ACCUMULATION;ENZIME:DPD
FLUOROURACIL;DPYD;rs1801158;TT;OTHER;INCREASED_ACTIVITY;;DPYD
FLUOROURACIL;DPYD;rs188052243;C;LADME-PK;DECREASED_ACTIVITY;DRUG_ACCUMULATION;ENZIME:DPD
PREGNENOLONE;SULT2B1;rs527454384;T;LADME-PK;DECREASED_ENZYME_ACTIVITY;;SULT2B1
FLUOROURACIL;DPYD;rs61757362;A;LADME-PK;DECREASED_ACTIVITY;DRUG_ACCUMULATION;ENZIME:DPD
ARACHIDONIC ACID;CYP4F2;rs2108622;T;LADME-PD;DECREASED_CATALYTIC_ACTIVITY;INCREASED_RISK;CYP4F2
NICOTINE;CYP2A6;CYP2A6*1, CYP2A6*17, CYP2A6*35;*17 + *35;LADME-PK;DECREASED_CATALYTIC_ACTIVITY;INCREASED_RISK;CYP2A6
BUPROPION;CYP2B6;rs148009906;A;LADME-PK;DECREASED_CATALYTIC_ACTIVITY;INCREASED_RISK;CYP2B6
ELEXACAFTOR, TEZACAFTOR;CFTR;rs397508293;T;EFFICACY;INCREASED_ACTIVITY;;CFTR
FLUOROURACIL;DPYD;rs1801268;A;LADME-PK;DECREASED_ACTIVITY;DRUG_ACCUMULATION;ENZIME:DPD
BUPROPION;CYP2B6;rs200458614;A;LADME-PK;DECREASED_CATALYTIC_ACTIVITY;INCREASED_RISK;CYP2B6
EFAVIRENZ;CYP2B6;rs764288403;A;LADME-PK;DECREASED_CATALYTIC_ACTIVITY;INCREASED_RISK;CYP2B6
EFAVIRENZ;CYP2B6;rs200238771;A;LADME-PK;DECREASED_CATALYTIC_ACTIVITY;INCREASED_RISK;CYP2B6
FLUOROURACIL;DPYD;rs367619008;C;LADME-PK;DECREASED_ACTIVITY;DRUG_ACCUMULATION;ENZIME:DPD
EFAVIRENZ;CYP2B6;rs200458614;A;LADME-PK;DECREASED_CATALYTIC_ACTIVITY;INCREASED_RISK;CYP2B6
NICOTINE;CYP2A6;rs56113850;CC + CT;LADME-PK;INCREASED_ACTIVITY;;CYP2A6
FLUOROURACIL;DPYD;rs758649719;T;LADME-PK;DECREASED_ACTIVITY;DRUG_ACCUMULATION;ENZIME:DPD
NICOTINE;CYP2A6;rs7259706;TT;LADME-PK;INCREASED_ACTIVITY;;CYP2A6
FLUOROURACIL;DPYD;rs369103276;G;LADME-PK;DECREASED_ACTIVITY;DRUG_ACCUMULATION;ENZIME:DPD
VANDETANIB;CYP3A4;CYP3A4*1, CYP3A4*6, CYP3A4*30;*6 + *30;LADME-PK;DECREASED_CATALYTIC_ACTIVITY;INCREASED_RISK;CYP3A4
NICOTINE;CYP2A6;rs28399453;AA + AG;LADME-PK;INCREASED_ACTIVITY;;CYP2A6
NICOTINE;CYP2A6;rs8192733;CC + CG;LADME-PK;INCREASED_ACTIVITY;;CYP2A6
EFAVIRENZ;CYP2B6;rs148009906;A;LADME-PK;DECREASED_CATALYTIC_ACTIVITY;INCREASED_RISK;CYP2B6
PREGNENOLONE;SULT2B1;rs777924668;G;LADME-PK;DECREASED_ENZYME_ACTIVITY;;SULT2B1
FLUOROURACIL;DPYD;rs55674432;A;LADME-PK;DECREASED_ACTIVITY;DRUG_ACCUMULATION;ENZIME:DPD
FLUOROURACIL;DPYD;rs55886062;CC;OTHER;DECREASED_ACTIVITY;DRUG_ACCUMULATION;ENZIME:DPD
LETROZOLE;CYP2A6;CYP2A6*1, CYP2A6*4, CYP2A6*7, CYP2A6*9;*1/*4 + *1/*7 + *4/*4 + *4/*9;LADME-PK;DECREASED_ENZYME_ACTIVITY;;CYP2A6
NICOTINE;CYP2A6;rs7260629;GG;LADME-PK;INCREASED_ACTIVITY;;CYP2A6
FLUOROURACIL;DPYD;rs1801265;GG;OTHER;INCREASED_ACTIVITY;;DPYD
DEXTROMETHORPHAN;CYP2D6;CYP2D6*1, CYP2D6*89, CYP2D6*92, CYP2D6*93, CYP2D6*96;*89 + *92 + *93 + *96;LADME-PK;DECREASED_CATALYTIC_ACTIVITY;INCREASED_RISK;CYP2D6
PREGNENOLONE;SULT2B1;rs777140014;A;LADME-PK;DECREASED_ENZYME_ACTIVITY;;SULT2B1
TESTOSTERONE;CYP3A5;rs55817950;A;LADME-PK;DECREASED_ENZYME_ACTIVITY;;CYP3A5
NIFEDIPINE;CYP3A5;rs72552791;C;LADME-PK;DECREASED_ENZYME_ACTIVITY;;CYP3A5
PREGNENOLONE;SULT2B1;rs774212320;T;LADME-PK;DECREASED_ENZYME_ACTIVITY;;SULT2B1
;ENZYME:CYP2C9;rs762081829;T;OTHER;DECREASED_EXPRESSION;;ENZYME:CYP2C9protein
;SLCO1B1;SLCO1B1*1, SLCO1B1*14;*14;OTHER;INCREASED_EXPRESSION;;SLCO1B1protein
;VDR;rs11568820;T;OTHER;INCREASED_STEADY-STATE-LEVEL;;CYP3A4protein
;A2M;rs669;T;LADME-PK;INCREASED_STEADY-STATE-LEVEL;;A2Mprotein
;SLCO1B1;SLCO1B1*1, SLCO1B1*37;*37;OTHER;INCREASED_EXPRESSION;;SLCO1B1protein
;NAMPT;rs1319501;CC + CT;OTHER;DECREASED_STEADY-STATE-LEVEL;;NAMPcTprotein
;DPYD;rs1801160;T;OTHER;INCREASED_EXPRESSION;;DPYDprotein
;NAMPT;rs3801266;CC + CT;OTHER;INCREASED_STEADY-STATE-LEVEL;;NAMPcTprotein
;SLCO1B1;SLCO1B1*1, SLCO1B1*20;*20;OTHER;INCREASED_EXPRESSION;;SLCO1B1protein
;ABCC11;rs17822471;AA + AG;OTHER;DECREASED_EXPRESSION;;ABCC11protein
;ENZYME:CYP2C9;rs771237265;C;OTHER;DECREASED_EXPRESSION;;ENZYME:CYP2C9protein
;ENZYME:CYP2C9;rs761895497;C;OTHER;DECREASED_EXPRESSION;;ENZYME:CYP2C9protein
;ENZYME:CYP2C19;rs183701923;T;OTHER;DECREASED_EXPRESSION;;ENZYME:CYP2C19protein
;DPYD;rs748620513;G;OTHER;INCREASED_EXPRESSION;;DPYDprotein
;ENZYME:CYP2C19;rs61311738;T;OTHER;DECREASED_EXPRESSION;;ENZYME:CYP2C19protein
;TPMT;TPMT*1, TPMT*2, TPMT*3A, TPMT*3C;*1/*2 + *1/*3A + *1/*3C;;DECREASED_ENZYME_ACTIVITY;;TPMTprotein
;DPYD;rs143879757;A;OTHER;INCREASED_EXPRESSION;;DPYDprotein
;DPYD;rs1212037891;T;OTHER;INCREASED_EXPRESSION;;DPYDprotein
;DPYD;rs72549306;A;OTHER;INCREASED_EXPRESSION;;DPYDprotein
;ENZYME:CYP2C19;rs140278421;A;OTHER;DECREASED_EXPRESSION;;ENZYME:CYP2C19protein
DOXORUBICIN;CBR1;rs9024;GG;LADME-PK;INCREASED_CATALYTIC_ACTIVITY;;CBR1
DOXORUBICIN;CBR1;rs9024;GG;LADME-PK;INCREASED_CATALYTIC_ACTIVITY;;CBR1
;ADRB2;rs1042713;G;OTHER;DECREASED_ACTIVITY;;ADRB2
;NOS3;rs1799983;GT + TT;;DECREASED_EXPRESSION;;NOS3mRNA
;IL18;rs5744247;CC + CG;OTHER;INCREASED_EXPRESSION;;IL18mRNA
;IL18;rs1946518;GG + GT;OTHER;INCREASED_EXPRESSION;;IL18mRNA
;CYP3A5;rs776746;CC;OTHER;DECREASED_EXPRESSION;;CYP3A5mRNA
;CYP3A5;CYP3A5*1, CYP3A5*3;*1/*1 + *1/*3;LADME-PD;DECREASED_EXPRESSION;;HDAC2mRNA
;CYP3A5;rs776746;TT;OTHER;INCREASED_EXPRESSION;;CYP3A5mRNA
;CYP3A5;CYP3A5*1, CYP3A5*3;*1/*1 + *1/*3;LADME-PD;DECREASED_EXPRESSION;;FKBP5mRNA
;CYP3A5;CYP3A5*1, CYP3A5*3;*1/*1 + *1/*3;LADME-PD;DECREASED_EXPRESSION;;NR3C1mRNA
;CYP3A5;CYP3A5*1, CYP3A5*3;*1/*1 + *1/*3;LADME-PD;DECREASED_EXPRESSION;;GLCCI1mRNA
;ERCC1;rs2298881;A;OTHER;DECREASED_EXPRESSION;;ERCC1mRNA
;HSPA5;rs430397;TT;OTHER;INCREASED_EXPRESSION;;HSPA5mRNA
;CCND1;rs9344;AA + AG;OTHER;INCREASED_TRANSCRIPTION;;GENE:CCND1mRNA
;ABCC2;rs113646094;CG;OTHER;INCREASED_EXPRESSION;;ABCC2mRNA
;ABCB1;rs1128503;GG;;INCREASED_EXPRESSION;;ABCB1mRNA
;XRCC4;rs2075685;T;OTHER;INCREASED_EXPRESSION;;XRCC4mRNA
;XRCC4;rs10040363;G;OTHER;INCREASED_EXPRESSION;;ERCC1mRNA
;GCLC;rs761142;CC;OTHER;DECREASED_EXPRESSION;;GCLCmRNA
;BCL2L11;rs724710;T;OTHER;DECREASED_EXPRESSION;;BCL2L11mRNA
;EPO;rs1617640;AA;OTHER;INCREASED_EXPRESSION;;EPOmRNA
;KDR;rs34231037;G;OTHER;DECREASED_STEADY-STATE-LEVEL;;KDR
METHOTREXATE;GGH;rs11545078;A;LADME-PK;DECREASED_CLEARANCE;DRUG_ACCUMULATION;
;DPYD;rs1801265;G;LADME-PK;INCREASED_ACTIVITY;;DPYD
;FCER2;rs28364072;GG;;DECREASED_EXPRESSION;;FCER2
;DPYD;rs114096998;T;OTHER;DECREASED_CATALYTIC_ACTIVITY;INCREASED_RISK;DPYD
;DPYD;rs55886062;AC;OTHER;DECREASED_ACTIVITY;DRUG_ACCUMULATION;ENZIME:DPD
;MGMT;rs4751104;G;LADME-PK;INCREASED_TRANSCRIPTION;;GENE:MGMT
;ERCC2;rs1799793;TT;;INCREASED_EXPRESSION;;ERCC2
CISPLATIN;ERCC2;rs13181;GG;TOXICITY;DECREASED_SENSITIVITY;LIKELIHOOD_THERAPEUTIC_FAILURE;
;ERCC2;rs13181;GG;;INCREASED_EXPRESSION;;ERCC2
;GSTT1;rs1007888;T;LADME-PK;INCREASED_TRANSCRIPTION;;GENE:GSTT1
;KCNQ3;rs7818112;AA;OTHER;INCREASED_TRANSCRIPTION;;GENE:ABCB1
;GSK3B;rs334558;A;;INCREASED_TRANSCRIPTION;;GENE:GSK3B
CISPLATIN;GSTP1;rs1695;AG;TOXICITY;DECREASED_SENSITIVITY;LIKELIHOOD_THERAPEUTIC_FAILURE;
BUSULFAN;GSTM1;rs3754446;C;LADME-PK;INCREASED_CLEARANCE;LIKELIHOOD_THERAPEUTIC_SUCCESS;
;DPYD;rs780025995;A;OTHER;DECREASED_CATALYTIC_ACTIVITY;INCREASED_RISK;DPYD
;F12;rs1801020;G;LADME-PK;INCREASED_ENZYME_ACTIVITY;;F12
;ERCC1;rs11615;GG;;INCREASED_EXPRESSION;;ERCC1
;IL7;rs16906115;AA + AG;OTHER;INCREASED_EXPRESSION;;IL7
;F3;rs841698;T;;INCREASED_EXPRESSION;;ABCD3
;DPYD;rs56038477;CT + TT;LADME-PK;DECREASED_ACTIVITY;DRUG_ACCUMULATION;ENZIME:DPD
;DPYD;rs2297595;C;OTHER;DECREASED_ACTIVITY;DRUG_ACCUMULATION;ENZIME:DPD
;DPYD;rs1801160;CT + TT;LADME-PK;DECREASED_ACTIVITY;DRUG_ACCUMULATION;ENZIME:DPD
;DPYD;rs2297595;CC + CT;LADME-PK;DECREASED_ACTIVITY;DRUG_ACCUMULATION;ENZIME:DPD
;HPR;rs2000999;G;OTHER;INCREASED_EXPRESSION;;HP
FLUOROURACIL;DPYD;rs4294451;A;TOXICITY;INCREASED_SENSITIVITY;;
;DPYD;rs115232898;CT;OTHER;DECREASED_ACTIVITY;DRUG_ACCUMULATION;ENZIME:DPD
;DPYD;rs4294451;T;OTHER;INCREASED_EXPRESSION;;DPYD
TAMOXIFEN;E2F7;rs310786;CC;OTHER;INCREASED_SENSITIVITY;;
;ECHDC1;rs6569487;AA;OTHER;INCREASED_TRANSCRIPTION;;GENE:ABCB1
;EGFR;rs712829;TT;;INCREASED_EXPRESSION;;EGFR
;HLA-G;rs1063320;C;OTHER;INCREASED_EXPRESSION;;HLA-G
CARBAMAZEPINE;HLA-DRB1;HLA-DRB1*07:01;*07:01;OTHER;INCREASED_SENSITIVITY;;
;DPYD;rs3918290;CT;OTHER;DECREASED_ACTIVITY;DRUG_ACCUMULATION;ENZIME:DPD
;IFNL3;rs4803217;C;OTHER;INCREASED_EXPRESSION;;IFNL3
;DPYD;rs3918290;CT;OTHER;DECREASED_ACTIVITY;DRUG_ACCUMULATION;ENZIME:DPD
CISPLATIN;ERCC1;rs11615;GG;TOXICITY;DECREASED_SENSITIVITY;LIKELIHOOD_THERAPEUTIC_FAILURE;
;DPYD;rs748639205;G;OTHER;DECREASED_CATALYTIC_ACTIVITY;INCREASED_RISK;DPYD
;DPYD;rs75017182;CG;OTHER;DECREASED_ACTIVITY;DRUG_ACCUMULATION;ENZIME:DPD
FLUOROURACIL;DPYD;rs3918290;CT;OTHER;DECREASED_CLEARANCE;DRUG_ACCUMULATION;
;IFNL4;rs11322783;TT/TT;OTHER;INCREASED_EXPRESSION;;IFNAR1
;DPYD;rs75017182;C;LADME-PK;DECREASED_ACTIVITY;DRUG_ACCUMULATION;ENZIME:DPD
;IMPDH2;rs121434586;A;OTHER;DECREASED_ENZYME_ACTIVITY;;IMPDH2
;DPYD;rs67376798;A;OTHER;DECREASED_ACTIVITY;DRUG_ACCUMULATION;ENZIME:DPD
CALCIUM;RYR1;rs118192167;AG;OTHER;INCREASED_STEADY-STATE-LEVEL;;
;MIR6076;rs1463411;G;OTHER;DECREASED_EXPRESSION;;P2RY12
DESMETHYLNAPROXEN;SULT1A1;rs28374453;G;LADME-PK;DECREASED_SULFATION;INCREASED_METABOLISM;
ACETAMINOPHEN;SULT1A1;rs28374453;G;LADME-PK;DECREASED_SULFATION;INCREASED_METABOLISM;
DESMETHYLNAPROXEN;SULT1A1;rs1042008;A;LADME-PK;DECREASED_SULFATION;DECREASED_METABOLISM;
ACETAMINOPHEN;SULT1A1;rs1042008;A;LADME-PK;DECREASED_SULFATION;DECREASED_METABOLISM;
DESMETHYLNAPROXEN;SULT1A1;rs758145522;T;LADME-PK;DECREASED_SULFATION;DECREASED_METABOLISM;
DESMETHYLNAPROXEN;SULT1A1;rs767487725;C;LADME-PK;DECREASED_SULFATION;DECREASED_METABOLISM;
ACETAMINOPHEN;SULT1A1;rs72547527;T;LADME-PK;DECREASED_SULFATION;DECREASED_METABOLISM;
TAPENTADOL;SULT1A1;rs1042008;A;LADME-PK;DECREASED_SULFATION;DECREASED_METABOLISM;
ACETAMINOPHEN;SULT1A1;rs767487725;C;LADME-PK;DECREASED_SULFATION;DECREASED_METABOLISM;
DESMETHYLNAPROXEN;SULT1A1;rs1042028;T;LADME-PK;DECREASED_SULFATION;DECREASED_METABOLISM;
ACETAMINOPHEN;SULT1A1;rs544820732;A;LADME-PK;DECREASED_SULFATION;DECREASED_METABOLISM;
;TBXAS1;rs6962291;AA;OTHER;DECREASED_STEADY-STATE-LEVEL;;TBX2
;TBXAS1;rs6962291;AA;OTHER;DECREASED_EXPRESSION;;TBXAS1
;TMPRSS11E;rs2168047;T;;INCREASED_EXPRESSION;;UGT2B4
;TNF;rs1800629;AA + AG;LADME-PK;INCREASED_ACTIVITY;;TNF
;TPH2;rs7305115;AA;OTHER;INCREASED_EXPRESSION;;TPH2
;TPH2;rs4290270;T;OTHER;INCREASED_EXPRESSION;;TPH2
THIOGUANINE;TPMT;TPMT*1, TPMT*7, TPMT*10, TPMT*12, TPMT*13;*7 + *10 + *12 + *13;LADME-PK;DECREASED_CLEARANCE;DRUG_ACCUMULATION;
;TPMT;TPMT*1, TPMT*3A, TPMT*3C;*3A + *3C;OTHER;DECREASED_ACTIVITY;;TPMT
ACETAMINOPHEN;SULT1A1;rs765399160;T;LADME-PK;DECREASED_SULFATION;INCREASED_METABOLISM;
;TPMT;TPMT*1, TPMT*3A, TPMT*3C, TPMT*24;*3A + *3C + *24;OTHER;DECREASED_EXPRESSION;;TPMT
ACETAMINOPHEN;SULT1A1;rs552524124;G;LADME-PK;DECREASED_SULFATION;DECREASED_METABOLISM;
TAPENTADOL;SULT1A1;rs1042028;T;LADME-PK;DECREASED_SULFATION;DECREASED_METABOLISM;
ATORVASTATIN, CERIVASTATIN, PRAVASTATIN;SLCO1B1;SLCO1B1*1, SLCO1B1*15;*15;LADME-PK;DECREASED_UPTAKE;;
PACLITAXEL;SLCO1B3;rs7311358;A;OTHER;DECREASED_TRANSPORT;;
ROSUVASTATIN;SLCO2B1;rs2306168;T;LADME-PK;DECREASED_UPTAKE;;
ROSUVASTATIN;SLCO2B1;rs142693902;A;LADME-PK;DECREASED_UPTAKE;;
ROSUVASTATIN;SLCO2B1;rs35199625;A;LADME-PK;DECREASED_UPTAKE;;
METHOTREXATE;SOD2;rs4880;G;TOXICITY;DECREASED_SENSITIVITY;LIKELIHOOD_THERAPEUTIC_FAILURE;
;SPAG16;rs35945601;CC;OTHER;INCREASED_TRANSCRIPTION;;GENE:ABCB1
;SQSTM1;rs10277;C;LADME-PK;INCREASED_TRANSCRIPTION;;GENE:SQSTM1
;STXBP4;rs9303363;AA;OTHER;INCREASED_TRANSCRIPTION;;GENE:ABCB1
DESMETHYLNAPROXEN;SULT1A1;rs552524124;G;LADME-PK;DECREASED_SULFATION;DECREASED_METABOLISM;
TAPENTADOL;SULT1A1;rs758145522;T;LADME-PK;DECREASED_SULFATION;DECREASED_METABOLISM;
TAPENTADOL;SULT1A1;rs72547527;T;LADME-PK;DECREASED_SULFATION;DECREASED_METABOLISM;
TAPENTADOL;SULT1A1;rs544820732;A;LADME-PK;DECREASED_SULFATION;DECREASED_METABOLISM;
TAPENTADOL;SULT1A1;rs767487725;C;LADME-PK;DECREASED_SULFATION;DECREASED_METABOLISM;
DESMETHYLNAPROXEN;SULT1A1;rs544820732;A;LADME-PK;DECREASED_SULFATION;DECREASED_METABOLISM;
ACETAMINOPHEN;SULT1A1;rs1042028;T;LADME-PK;DECREASED_SULFATION;DECREASED_METABOLISM;
DESMETHYLNAPROXEN;SULT1A1;rs72547527;T;LADME-PK;DECREASED_SULFATION;DECREASED_METABOLISM;
TAPENTADOL;SULT1A1;rs552524124;G;LADME-PK;DECREASED_SULFATION;DECREASED_METABOLISM;
TAPENTADOL;SULT1A1;rs28374453;G;LADME-PK;DECREASED_SULFATION;INCREASED_METABOLISM;
ACETAMINOPHEN;SULT1A1;rs758145522;T;LADME-PK;DECREASED_SULFATION;DECREASED_METABOLISM;
ATORVASTATIN, CERIVASTATIN, PRAVASTATIN;SLCO1B1;SLCO1B1*1, SLCO1B1*5;*5;LADME-PK;DECREASED_UPTAKE;;
MERCAPTOPURINE;TPMT;TPMT deficiency;;TOXICITY, LADME-PK;INCREASED_CONCENTRATIONS;;
CISPLATIN;TPMT;TPMT*1, TPMT*3A;*3A;TOXICITY;INCREASED_SENSITIVITY;;
SN-38;UGT1A9;rs2741049;CT + TT;LADME-PK;INCREASED_CLEARANCE;LIKELIHOOD_THERAPEUTIC_SUCCESS;
;UGT1A9;rs3832043;T/del + TT;LADME-PK;INCREASED_FORMATION;;UGT1A9
;UGT1A9;rs2741049;TT;LADME-PK;INCREASED_FORMATION;;UGT1A1
SN-38;UGT1A9;rs3806598;AA;LADME-PK;INCREASED_CLEARANCE;LIKELIHOOD_THERAPEUTIC_SUCCESS;
;UGT1A9;rs3832043;T/del + TT;LADME-PK;INCREASED_FORMATION;;UGT1A1
SN-38;UGT1A9;rs3832043;T/del + TT;LADME-PK;INCREASED_CLEARANCE;LIKELIHOOD_THERAPEUTIC_SUCCESS;
;UGT1A9;rs2741049;CT + TT;LADME-PK;INCREASED_FORMATION;;UGT1A9
OLANZAPINE;UGT2B10;rs61750900;GT + TT;LADME-PK;DECREASED_GLUCURONIDATION;;
LORAZEPAM;UGT2B15;rs1902023;AA;LADME-PK;DECREASED_CLEARANCE;DRUG_ACCUMULATION;
OXAZEPAM;UGT2B15;rs1902023;A;OTHER;DECREASED_GLUCURONIDATION;;
;UGT2B17;rs6817882;C;OTHER;INCREASED_EXPRESSION;;UGT2B17
;UGT2B4;rs4557343;T;;INCREASED_EXPRESSION;;UGT2B15
BUPRENORPHINE;UGT2B7;rs7438135;A;LADME-PK;INCREASED_GLUCURONIDATION;;
;UMPS;rs1801019;C;LADME-PK;INCREASED_EXPRESSION;;UMPS
;VKORC1;rs56314408;C;OTHER;INCREASED_TRANSCRIPTION;;GENE:VKORC1
;VKORC1;rs9923231;T;;DECREASED_EXPRESSION;;VKORC1
;WBP2NL;rs5758550;AG + GG;OTHER;INCREASED_EXPRESSION;;CYP2D6
;YAP1;rs1820453;C;;DECREASED_TRANSCRIPTION;;GENE:YAP1
;YEATS4;rs7297610;CC;LADME-PK;INCREASED_EXPRESSION;;YEATS4
RALOXIFENE;UGT1A8;UGT1A8*1a, UGT1A8*2;*2/*2;LADME-PK;INCREASED_CLEARANCE;LIKELIHOOD_THERAPEUTIC_SUCCESS;
THIOGUANINE;TPMT;TPMT*1, TPMT*16;*16;LADME-PK;DECREASED_CLEARANCE;DRUG_ACCUMULATION;
VALPROIC ACID;UGT1A6;rs1105879;C;LADME-PK;INCREASED_GLUCURONIDATION;;
CLOZAPINE 5-N-GLUCURONIDE, DESMETHYLCLOZAPINE GLUCURONIDE;UGT1A4;rs2011425;G;LADME-PK;INCREASED_FORMATION;;
CISPLATIN;TPMT;TPMT*1, TPMT*3A;*3A;TOXICITY;INCREASED_SENSITIVITY;;
;TXLNB;rs9495425;CC;OTHER;INCREASED_TRANSCRIPTION;;GENE:ABCB1
;UGT1A1;rs4124874;GG + GT;LADME-PK;DECREASED_FORMATION;;UGT1A1
SN-38;UGT1A1;rs4124874;GG + GT;LADME-PK;DECREASED_CLEARANCE;DRUG_ACCUMULATION;
OXAZEPAM;UGT1A1;rs10929302;A;OTHER;DECREASED_GLUCURONIDATION;;
;UGT1A1;rs10929302;A;OTHER;DECREASED_CONCENTRATIONS;;UGT1A1
;UGT1A1;rs28967009;A;OTHER;INCREASED_EXPRESSION;;UGT1A1
SN-38;UGT1A1;rs4148323;AG;LADME-PK;DECREASED_CLEARANCE;DRUG_ACCUMULATION;
;UGT1A1;rs4148323;AG;LADME-PK;DECREASED_FORMATION;;UGT1A1
OXAZEPAM;UGT1A1;rs887829;T;OTHER;DECREASED_GLUCURONIDATION;;
OXAZEPAM;UGT1A1;rs4124874;G;OTHER;ASSOCIATED_GLUCURONIDATION;;
;UGT1A1;UGT1A1*1, UGT1A1*28;*28;OTHER;DECREASED_CONCENTRATIONS;;UGT1A1
CLOZAPINE;UGT1A1;UGT1A1*1, UGT1A1*28;*28/*28;LADME-PK;DECREASED_METABOLISM;;
BELINOSTAT;UGT1A1;UGT1A1*1, UGT1A1*28;*28;LADME-PK;DECREASED_METABOLISM;;
;UGT1A1;rs887829;T;OTHER;DECREASED_CONCENTRATIONS;;UGT1A1
;UGT1A1;rs4124874;G;OTHER;DECREASED_CONCENTRATIONS;;UGT1A1
RALOXIFENE 6-GLUCURONIDE;UGT1A1;UGT1A1*1, UGT1A1*28;*28;LADME-PK;DECREASED_FORMATION;;
;UGT1A1;rs11568319;CG;LADME-PK;DECREASED_FORMATION;;UGT1A1
;UGT1A3;rs7604115;T;OTHER;INCREASED_EXPRESSION;;UGT1A3
OLANZAPINE;UGT1A4;UGT1A4*1a, UGT1A4*3a;*3a;LADME-PK;INCREASED_GLUCURONIDATION;;
;SLCO1B1;SLCO1B1*1, SLCO1B1*15;*15;OTHER;DECREASED_EXPRESSION;;SLCO1B1
ATRASENTAN;SLCO1B1;SLCO1B1*1, SLCO1B1*14, SLCO1B1*37;*14;LADME-PK;DECREASED_TRANSPORT;;
ATRASENTAN;SLCO1B1;SLCO1B1*1, SLCO1B1*9, SLCO1B1*37;*9;LADME-PK;DECREASED_TRANSPORT;;
;PACSIN2;rs2413739;CT + TT;LADME-PK;DECREASED_ACTIVITY;DRUG_ACCUMULATION;TPMT
;PHETA2, SMDT1;rs1807493;G;LADME-PK;INCREASED_EXPRESSION;;CYP2D6
;PITPNM2;rs12425009;C;;DECREASED_EXPRESSION;;ABCB9
;PKNOX1;rs2839629;A;OTHER;INCREASED_EXPRESSION;;PKNOX1
;PKNOX1;rs2839629;A;OTHER;INCREASED_EXPRESSION;;CBS
;PLG;rs783145;G;LADME-PK;DECREASED_TRANSCRIPTION;;GENE:PRSS55
;PLG;rs783145;G;LADME-PK;INCREASED_TRANSCRIPTION;;GENE:PLG
;PLXNB3;rs4898439;A;;INCREASED_EXPRESSION;;ABCD1
;POR;rs2868177;AG;EFFICACY;INCREASED_ENZYME_ACTIVITY;;CYP2B6
;PPARA;rs4253728;AA;LADME-PK;DECREASED_CONCENTRATIONS;;CYP3A4
;PROM1;rs2286455;CC;;DECREASED_EXPRESSION;;PROM1
;PSMB8, TAP1, TAP2;rs2071543;T;;INCREASED_EXPRESSION;;TAP2
;PSMB8, TAP2;rs9357155;A;;INCREASED_EXPRESSION;;TAP2
;RALGAPA2;rs3827963;GG;OTHER;INCREASED_TRANSCRIPTION;;GENE:ABCB1
DOXORUBICIN;RARG;rs2229774;A;TOXICITY;INCREASED_SENSITIVITY;;
;RARG;rs2229774;A;OTHER;DECREASED_PROTEIN-STABILITY;;RARG
;REDIC1;rs10783969;T;;INCREASED_EXPRESSION;;ABCD2
;RGMA;rs7165938;GG;OTHER;INCREASED_TRANSCRIPTION;;GENE:ABCB1
CAFFEINE;RYR1;rs193922753;T;OTHER;INCREASED_SENSITIVITY;;
;ORMDL3;rs2872507;AG + GG;LADME-PK;INCREASED_EXPRESSION;;ORMDL3
CAFFEINE, CHLOROCRESOL, HALOTHANE;RYR1;rs118204423;C;OTHER;INCREASED_SENSITIVITY;;
ETHANOL;OPRM1;rs1799971;GG;EFFICACY;DECREASED_SENSITIVITY;LIKELIHOOD_THERAPEUTIC_FAILURE;
;NT5C2;rs11191612;GG;LADME-PK;INCREASED_TRANSCRIPTION;;GENE:NT5C2
PAROMOMYCIN;MT-RNR1;rs267606619;T;LADME-PD;INCREASED_SENSITIVITY;;
GEMCITABINE;MTHFR;rs1801131;GG + GT;TOXICITY;INCREASED_SENSITIVITY;;
;NAF1;rs17571991;AA;OTHER;INCREASED_TRANSCRIPTION;;GENE:ABCC1
SOLITHROMYCIN;NAT2;NAT2*4, NAT2*5, NAT2*6, NAT2*7, NAT2*14;*4;LADME-PK;INCREASED_METABOLISM;;
;NAT2;rs4646244;A;OTHER;DECREASED_TRANSCRIPTION;;GENE:NAT2
;NCOA1;rs1804645;T;;INCREASED_HALF-LIFE;;NCOA1
;NFATC2;rs6021191;T;OTHER;INCREASED_EXPRESSION;;NFATC2
;NHLH1;rs11265375;T;OTHER;INCREASED_LUCIFERASE_ACTIVITY;;
;NQO1;rs1800566;AA;;DECREASED_ENZYME_ACTIVITY;;NQO1
;NQO1;rs1800566;A;;DECREASED_EXPRESSION;;NQO1
MIDAZOLAM;NR1I2;rs1464602;G;LADME-PK;INCREASED_CLEARANCE;LIKELIHOOD_THERAPEUTIC_SUCCESS;
MIDAZOLAM;NR1I2;rs1464603;G;LADME-PK;INCREASED_CLEARANCE;LIKELIHOOD_THERAPEUTIC_SUCCESS;
;NRP2;rs10932125;C;;INCREASED_EXPRESSION;;CYP1B1
CLADRIBINE, FLUOROURACIL, GEMCITABINE;NT5C1A;rs201045130;G;OTHER;DECREASED_SENSITIVITY;LIKELIHOOD_THERAPEUTIC_FAILURE;
CLADRIBINE, FLUOROURACIL, GEMCITABINE;NT5C1A;rs370457585;T;OTHER;DECREASED_SENSITIVITY;LIKELIHOOD_THERAPEUTIC_FAILURE;
CLADRIBINE, FLUOROURACIL, GEMCITABINE;NT5C1A;rs374150125;A;OTHER;DECREASED_SENSITIVITY;LIKELIHOOD_THERAPEUTIC_FAILURE;
CYTARABINE;NT5C2;rs1163075;G;EFFICACY;DECREASED_SENSITIVITY;LIKELIHOOD_THERAPEUTIC_FAILURE;
;NT5C2;rs1163075;G;LADME-PK;INCREASED_TRANSCRIPTION;;GENE:NT5C2
CYTARABINE;NT5C2;rs11191612;GG;EFFICACY;DECREASED_SENSITIVITY;LIKELIHOOD_THERAPEUTIC_FAILURE;
;NT5E;rs9450278;A;;DECREASED_EXPRESSION;;NT5E
CHLOROCRESOL;RYR1;rs121918596;del;OTHER;INCREASED_SENSITIVITY;;
CAFFEINE;RYR1;rs193922843;T;DOSAGE;INCREASED_SENSITIVITY;;
CAFFEINE;RYR1;rs193922816;T;OTHER;INCREASED_SENSITIVITY;;
CAFFEINE;RYR1;rs118192176;A;OTHER;INCREASED_SENSITIVITY;;
;SEMA6A;rs3806915;A;OTHER;INCREASED_LUCIFERASE_ACTIVITY;;
;SEPTIN3, WBP2NL;rs1062753;G;LADME-PK;INCREASED_EXPRESSION;;CYP2D6
RANITIDINE;SLC22A1;rs12208357;T;LADME-PK;DECREASED_TRANSPORT;;
RANITIDINE;SLC22A1;rs72552763;del;LADME-PK;DECREASED_TRANSPORT;;
RANITIDINE;SLC22A1;rs34130495;A;LADME-PK;DECREASED_TRANSPORT;;
;SLC22A3;rs2076828;G;OTHER;DECREASED_EXPRESSION;;SLC22A3
;SLC22A3;rs884742;C;LADME-PK;INCREASED_TRANSCRIPTION;;GENE:SLC22A3
;SLC22A3;rs555754;AA;;INCREASED_EXPRESSION;;SLC22A3
ADEFOVIR DIPIVOXIL;SLC22A6;rs11568634;T;OTHER;DECREASED_UPTAKE;;
CEFOTAXIME;SLC22A8;rs11568482;A;LADME-PK;DECREASED_TRANSPORT;;
GEMCITABINE TRIPHOSPHATE;SLC28A3;rs7867504;CC;LADME-PK;INCREASED_FORMATION;;
DOXORUBICIN;SLC28A3;rs11140490;AA;TOXICITY;INCREASED_SENSITIVITY;;
;SLC29A1;rs731780;G;OTHER;INCREASED_EXPRESSION;;SLC29A1
;SLC29A1;rs70914;A;;INCREASED_EXPRESSION;;SLC29A1
;SLCO1A2;rs4148981;T;;DECREASED_EXPRESSION;;SLCO1A2
ATRASENTAN;SLCO1B1;SLCO1B1*1, SLCO1B1*15, SLCO1B1*37;*15;LADME-PK;DECREASED_TRANSPORT;;
;SLCO1B1;rs4149056;C;OTHER;DECREASED_EXPRESSION;;SLCO1B1
ATRASENTAN;SLCO1B1;SLCO1B1*1, SLCO1B1*5, SLCO1B1*37;*5;LADME-PK;DECREASED_TRANSPORT;;
CAFFEINE, HALOTHANE;RYR1;rs28933397;CT;OTHER;ASSOCIATED_SENSITIVITY;;
CAFFEINE, CHLOROCRESOL;RYR1;rs186983396;T;LADME-PK;INCREASED_SENSITIVITY;;
CAFFEINE, CHLOROCRESOL;RYR1;rs118192178;T;OTHER;INCREASED_SENSITIVITY;;
CHLOROCRESOL;RYR1;rs118192124;T;OTHER;INCREASED_SENSITIVITY;;
CAFFEINE;RYR1;rs118192167;G;OTHER;INCREASED_SENSITIVITY;;
CAFFEINE;RYR1;rs193922803;T;DOSAGE;INCREASED_SENSITIVITY;;
CAFFEINE;RYR1;rs118192122;A;OTHER;INCREASED_SENSITIVITY;;
CAFFEINE;RYR1;rs193922809;A;OTHER;INCREASED_SENSITIVITY;;
CAFFEINE;RYR1;rs118192168;A;DOSAGE;INCREASED_SENSITIVITY;;
CAFFEINE;RYR1;rs193922832;A;DOSAGE;INCREASED_SENSITIVITY;;
CAFFEINE;RYR1;rs112563513;A;DOSAGE;INCREASED_SENSITIVITY;;
CAFFEINE, CHLOROCRESOL, HALOTHANE;RYR1;rs121918594;A;OTHER;INCREASED_SENSITIVITY;;
CAFFEINE;RYR1;rs193922878;G;OTHER;INCREASED_SENSITIVITY;;
;MIR27A;rs895819;CC;OTHER;INCREASED_EXPRESSION;;MIR27A
CAFFEINE;RYR1;rs118192161;T;OTHER;INCREASED_SENSITIVITY;;
CAFFEINE;RYR1;rs118192177;T;OTHER;INCREASED_SENSITIVITY;;
CAFFEINE;RYR1;rs118192167;AG;OTHER;INCREASED_SENSITIVITY;;
CAFFEINE, HALOTHANE;RYR1;rs118192172;CT;OTHER;ASSOCIATED_SENSITIVITY;;
CAFFEINE, HALOTHANE;RYR1;rs193922772;GT;OTHER;ASSOCIATED_SENSITIVITY;;
CAFFEINE, HALOTHANE;RYR1;rs118192175;CT;OTHER;ASSOCIATED_SENSITIVITY;;
CAFFEINE, HALOTHANE;RYR1;rs193922747;CT;OTHER;ASSOCIATED_SENSITIVITY;;
CAFFEINE, HALOTHANE;RYR1;rs118192176;AG;OTHER;ASSOCIATED_SENSITIVITY;;
CHLOROCRESOL;RYR1;rs118192124;T;OTHER;INCREASED_SENSITIVITY;;
CAFFEINE, CHLOROCRESOL;RYR1;rs118192178;G;OTHER;INCREASED_SENSITIVITY;;
CAFFEINE, CHLOROCRESOL;RYR1;rs193922818;A;OTHER;INCREASED_SENSITIVITY;;
;;rs2000068;G;;INCREASED_EXPRESSION;;ABCA1
PRIMAQUINE;CYP2D6;CYP2D6*1, CYP2D6*17, CYP2D6*18, CYP2D6*35, CYP2D6*39, CYP2D6*53;*17 + *18 + *35 + *39 + *53;LADME-PK;DECREASED_CLEARANCE;DRUG_ACCUMULATION;
;DPYD;rs1801158;T;OTHER;DECREASED_ACTIVITY;DRUG_ACCUMULATION;ENZIME:DPD
EFAVIRENZ;CYP2B6;rs142421637;T;LADME-PK;DECREASED_CLEARANCE;DRUG_ACCUMULATION;
EFAVIRENZ;CYP2B6;rs373442191;A;LADME-PK;INCREASED_CLEARANCE;LIKELIHOOD_THERAPEUTIC_SUCCESS;
PROPOFOL;CYP2B6;rs752695347;T;LADME-PK;DECREASED_CLEARANCE;DRUG_ACCUMULATION;
PROPOFOL;CYP2B6;rs142421637;T;LADME-PK;DECREASED_CLEARANCE;DRUG_ACCUMULATION;
PROPOFOL;CYP2B6;rs1282926098;T;LADME-PK;INCREASED_CLEARANCE;LIKELIHOOD_THERAPEUTIC_SUCCESS;
PROPOFOL;CYP2B6;rs1969136524;C;LADME-PK;DECREASED_CLEARANCE;DRUG_ACCUMULATION;
EFAVIRENZ;CYP2B6;rs773494867;C;LADME-PK;DECREASED_CLEARANCE;DRUG_ACCUMULATION;
EFAVIRENZ;CYP2B6;rs1969376664;T;LADME-PK;DECREASED_CLEARANCE;DRUG_ACCUMULATION;
PROPOFOL;CYP2B6;rs138264188;T;LADME-PK;DECREASED_CLEARANCE;DRUG_ACCUMULATION;
PROPOFOL;CYP2B6;rs373442191;A;LADME-PK;INCREASED_CLEARANCE;LIKELIHOOD_THERAPEUTIC_SUCCESS;
EFAVIRENZ;CYP2B6;rs1969255598;T;LADME-PK;INCREASED_CLEARANCE;LIKELIHOOD_THERAPEUTIC_SUCCESS;
EFAVIRENZ;CYP2B6;rs1248477767;G;LADME-PK;INCREASED_CLEARANCE;LIKELIHOOD_THERAPEUTIC_SUCCESS;
EFAVIRENZ;CYP2B6;rs750671397;G;LADME-PK;INCREASED_CLEARANCE;LIKELIHOOD_THERAPEUTIC_SUCCESS;
EFAVIRENZ;CYP2B6;rs141666881;A;LADME-PK;INCREASED_CLEARANCE;LIKELIHOOD_THERAPEUTIC_SUCCESS;
EFAVIRENZ;CYP2B6;rs1968919352;G;LADME-PK;INCREASED_CLEARANCE;LIKELIHOOD_THERAPEUTIC_SUCCESS;
EFAVIRENZ;CYP2B6;rs1282926098;T;LADME-PK;INCREASED_CLEARANCE;LIKELIHOOD_THERAPEUTIC_SUCCESS;
R-EDDP, S-EDDP;CYP2B6;CYP2B6*1, CYP2B6*4;*4;LADME-PK;INCREASED_FORMATION;;
R-EDDP, S-EDDP;CYP2B6;CYP2B6*1, CYP2B6*5, CYP2B6*6, CYP2B6*7, CYP2B6*9, CYP2B6*17, CYP2B6*18, CYP2B6*19, CYP2B6*26;*5+ *17 + *6+ *7 + *9+ *19 + *26 + *18;LADME-PK;DECREASED_FORMATION;;
;CYP2B6;rs70950385;CA/CA;OTHER;DECREASED_ACTIVITY;;CYP2B6
EFAVIRENZ;CYP2B6;rs1969136524;C;LADME-PK;DECREASED_CLEARANCE;DRUG_ACCUMULATION;
EFAVIRENZ;CYP2B6;rs772413158;A;LADME-PK;DECREASED_CLEARANCE;DRUG_ACCUMULATION;
EFAVIRENZ;CYP2B6;rs752695347;T;LADME-PK;DECREASED_CLEARANCE;DRUG_ACCUMULATION;
EFAVIRENZ;CYP2B6;rs553968231;T;LADME-PK;DECREASED_CLEARANCE;DRUG_ACCUMULATION;
;CYP1A2;rs762551;A;;INCREASED_ACTIVITY;;CYP1A2
;CYP1A2;rs35694136;del;;DECREASED_ACTIVITY;;CYP1A2
DACARBAZINE;CYP1A2;CYP1A2*1, CYP1A2*11;*11;LADME-PK;DECREASED_CLEARANCE;DRUG_ACCUMULATION;
;CYP1A2;rs762551;AA + AC;LADME-PK;INCREASED_TRANSCRIPTION;;GENE:CYP1A2
DACARBAZINE;CYP1A2;CYP1A2*1, CYP1A2*3;*3;LADME-PK;DECREASED_CLEARANCE;DRUG_ACCUMULATION;
;CYP2A6;rs8192720;AA + AG;;INCREASED_EXPRESSION;METABOLISM;ENZYME:CYP2A6
;CYP2A6;rs8192725;AG + GG;;INCREASED_EXPRESSION;METABOLISM;ENZYME:CYP2A6
;CYP2A6;rs28399433;AC + CC;;DECREASED_EXPRESSION;METABOLISM;ENZYME:CYP2A6
;CYP2A6;CYP2A6*4, CYP2A6*9;*4/*9;;DECREASED_EXPRESSION;METABOLISM;ENZYME:CYP2A6
;CYP2B6;CYP2B6*1, CYP2B6*27;*27;;DECREASED_EXPRESSION;;CYP2B6
COUMARIN;CYP2A6;rs28399454;T;LADME-PK;DECREASED_METABOLISM;;
COUMARIN;CYP2A6;CYP2A6*1, CYP2A6*4;*1/*4;LADME-PK;DECREASED_CLEARANCE;DRUG_ACCUMULATION;
COUMARIN;CYP2A6;CYP2A6*1, CYP2A6*9;*1/*9;LADME-PK;DECREASED_CLEARANCE;DRUG_ACCUMULATION;
;CYP2A6;CYP2A6*46;*46;;INCREASED_EXPRESSION;METABOLISM;ENZYME:CYP2A6
;CYP2A6;CYP2A6*1, CYP2A6*4;*4;;DECREASED_EXPRESSION;METABOLISM;ENZYME:CYP2A6
;CYP2A6;CYP2A6*46;*46;;INCREASED_TRANSCRIPTION;;GENE:CYP2A6
;CYP2B6;rs3745274;TT;OTHER;DECREASED_EXPRESSION;;CYP2B6
PROPOFOL;CYP2B6;rs553968231;T;LADME-PK;DECREASED_CLEARANCE;DRUG_ACCUMULATION;
PROPOFOL;CYP2B6;rs1969376664;T;LADME-PK;DECREASED_CLEARANCE;DRUG_ACCUMULATION;
PROPOFOL;CYP2B6;rs773494867;C;LADME-PK;DECREASED_CLEARANCE;DRUG_ACCUMULATION;
;CYP2A6;CYP2A6*46;*46;;INCREASED_EXPRESSION;METABOLISM;ENZYME:CYP2A6
3-CYANO-7-ETHOXYCOUMARIN;CYP2C19;CYP2C19*1, CYP2C19*8, CYP2C19*9, CYP2C19*10, CYP2C19*16, CYP2C19*19;*8 + *9 + *10 + *16 + *19;LADME-PK;DECREASED_CLEARANCE;DRUG_ACCUMULATION;
NEBIVOLOL;CYP2C19;CYP2C19*1, CYP2C19*6, CYP2C19*18, CYP2C19*30, CYP2C19*31, CYP2C19*32, CYP2C19*33;*30 + *31 + *32 + *33 + *6 + *18;LADME-PK;DECREASED_CLEARANCE;DRUG_ACCUMULATION;
MEPHENYTOIN;CYP2C19;CYP2C19*1, CYP2C19*10, CYP2C19*14, CYP2C19*19, CYP2C19*25, CYP2C19*26;*10 + *14 + *19 + *25 + *26;LADME-PK;DECREASED_CLEARANCE;DRUG_ACCUMULATION;
VORICONAZOLE;CYP2C19;CYP2C19*1, CYP2C19*6;*6;LADME-PK;DECREASED_CLEARANCE;DRUG_ACCUMULATION;
FLUOXETINE;CYP2C19;rs550527959;T;LADME-PK;DECREASED_CLEARANCE;DRUG_ACCUMULATION;
METHADONE;CYP2C19;rs1463550071;T;LADME-PK;DECREASED_CLEARANCE;DRUG_ACCUMULATION;
FLUOXETINE;CYP2C19;rs200346442;A;LADME-PK;DECREASED_CLEARANCE;DRUG_ACCUMULATION;
FLUOXETINE;CYP2C19;rs200150287;G;LADME-PK;DECREASED_CLEARANCE;DRUG_ACCUMULATION;
FLUOXETINE;CYP2C19;rs118203756;C;LADME-PK;DECREASED_CLEARANCE;DRUG_ACCUMULATION;
FLUVOXAMINE, OMEPRAZOLE;CYP2C19;CYP2C19*1, CYP2C19*15;*15;LADME-PK;INCREASED_SENSITIVITY;;
FLUVOXAMINE, OMEPRAZOLE;CYP2C19;CYP2C19*1, CYP2C19*18;*18;LADME-PK;INCREASED_SENSITIVITY;;
CELECOXIB, FLUOXETINE, KETOCONAZOLE, TICLOPIDINE;CYP2C19;CYP2C19*1, CYP2C19*18;*18;LADME-PK;DECREASED_SENSITIVITY;LIKELIHOOD_THERAPEUTIC_FAILURE;
FLUOXETINE;CYP2C19;rs778258371;A;LADME-PK;DECREASED_CLEARANCE;DRUG_ACCUMULATION;
CELECOXIB;CYP2C19;CYP2C19*1, CYP2C19*19;*19;LADME-PK;INCREASED_SENSITIVITY;;
CELECOXIB, FLUOXETINE, KETOCONAZOLE, SERTRALINE, TICLOPIDINE;CYP2C19;CYP2C19*1, CYP2C19*16;*16;LADME-PK;DECREASED_SENSITIVITY;LIKELIHOOD_THERAPEUTIC_FAILURE;
FLUOXETINE, FLUVOXAMINE, KETOCONAZOLE, OMEPRAZOLE, SERTRALINE, TICLOPIDINE, TRANYLCYPROMINE;CYP2C19;CYP2C19*1, CYP2C19*19;*19;LADME-PK;DECREASED_SENSITIVITY;LIKELIHOOD_THERAPEUTIC_FAILURE;
;ENZYME:CYP2C19;CYP2C19*1, CYP2C19*16;*16;OTHER;DECREASED_FORMATION;;ENZYME:CYP2C19
FLUCONAZOLE, FLUVOXAMINE, SERTRALINE;CYP2C19;CYP2C19*1, CYP2C19*11;*11;LADME-PK;INCREASED_SENSITIVITY;;
FLUOXETINE;CYP2C19;CYP2C19*1, CYP2C19*10;*10;LADME-PK;DECREASED_SENSITIVITY;LIKELIHOOD_THERAPEUTIC_FAILURE;
CELECOXIB, FLUOXETINE, KETOCONAZOLE, SERTRALINE, TROGLITAZONE;CYP2C19;CYP2C19*1, CYP2C19*9;*9;LADME-PK;DECREASED_SENSITIVITY;LIKELIHOOD_THERAPEUTIC_FAILURE;
FLUCONAZOLE, FLUVOXAMINE;CYP2C19;CYP2C19*1, CYP2C19*9;*9;LADME-PK;INCREASED_SENSITIVITY;;
OMEPRAZOLE;CYP2C19;CYP2C19*1, CYP2C19*10;*10;LADME-PK;DECREASED_CLEARANCE;DRUG_ACCUMULATION;
FLUCONAZOLE, FLUOXETINE, FLUVOXAMINE, KETOCONAZOLE, OMEPRAZOLE, SERTRALINE, TICLOPIDINE, TRANYLCYPROMINE, TROGLITAZONE;CYP2C19;CYP2C19*1, CYP2C19*8;*8;LADME-PK;DECREASED_SENSITIVITY;LIKELIHOOD_THERAPEUTIC_FAILURE;
FLUOXETINE, TRANYLCYPROMINE;CYP2C19;CYP2C19*1, CYP2C19*15;*15;LADME-PK;DECREASED_SENSITIVITY;LIKELIHOOD_THERAPEUTIC_FAILURE;
;CYP1A2;rs2069514;A;;DECREASED_ACTIVITY;;CYP1A2
MEPHENYTOIN, OMEPRAZOLE;CYP2C19;CYP2C19*1, CYP2C19*26;*26;LADME-PK;DECREASED_CLEARANCE;DRUG_ACCUMULATION;
VORICONAZOLE;CYP2C19;CYP2C19*1, CYP2C19*23;*23;LADME-PK;DECREASED_CLEARANCE;DRUG_ACCUMULATION;
CLOPIDOGREL;CYP2C19;CYP2C19*1, CYP2C19*10, CYP2C19*14, CYP2C19*19, CYP2C19*23, CYP2C19*25, CYP2C19*26;*10 + *14 + *19 + *23 + *25 + *26;LADME-PK;DECREASED_CLEARANCE;DRUG_ACCUMULATION;
FLUOXETINE;CYP2C19;rs370803989;A;LADME-PK;DECREASED_CLEARANCE;DRUG_ACCUMULATION;
FLUOXETINE;CYP2C19;rs145328984;T;LADME-PK;DECREASED_CLEARANCE;DRUG_ACCUMULATION;
FLUOXETINE;CYP2C19;rs763625282;A;LADME-PK;DECREASED_CLEARANCE;DRUG_ACCUMULATION;
FLUOXETINE;CYP2C19;rs147255955;T;LADME-PK;DECREASED_CLEARANCE;DRUG_ACCUMULATION;
FLUOXETINE;CYP2C19;rs3758581;G;LADME-PK;DECREASED_CLEARANCE;DRUG_ACCUMULATION;
FLUOXETINE;CYP2C19;rs559628884;A;LADME-PK;DECREASED_CLEARANCE;DRUG_ACCUMULATION;
FLUOXETINE;CYP2C19;rs764137538;T;LADME-PK;DECREASED_CLEARANCE;DRUG_ACCUMULATION;
FLUOXETINE;CYP2C19;rs1349931378;A;LADME-PK;DECREASED_CLEARANCE;DRUG_ACCUMULATION;
VORICONAZOLE;CYP2C19;CYP2C19*1, CYP2C19*33;*33;LADME-PK;DECREASED_CLEARANCE;DRUG_ACCUMULATION;
FLUOXETINE;CYP2C19;rs1463550071;T;LADME-PK;DECREASED_CLEARANCE;DRUG_ACCUMULATION;
METHADONE;CYP2C19;rs778258371;A;LADME-PK;DECREASED_CLEARANCE;DRUG_ACCUMULATION;
VORICONAZOLE;CYP2C19;CYP2C19*1, CYP2C19*18;*18;LADME-PK;DECREASED_CLEARANCE;DRUG_ACCUMULATION;
METHADONE;CYP2C19;rs72552267;A;LADME-PK;DECREASED_CLEARANCE;DRUG_ACCUMULATION;
METHADONE;CYP2C19;rs118203756;C;LADME-PK;DECREASED_CLEARANCE;DRUG_ACCUMULATION;
METHADONE;CYP2C19;rs764137538;T;LADME-PK;DECREASED_CLEARANCE;DRUG_ACCUMULATION;
METHADONE;CYP2C19;rs550527959;T;LADME-PK;DECREASED_CLEARANCE;DRUG_ACCUMULATION;
METHADONE;CYP2C19;rs1349931378;A;LADME-PK;DECREASED_CLEARANCE;DRUG_ACCUMULATION;
FLUOXETINE;CYP2C19;rs770829708;A;LADME-PK;DECREASED_CLEARANCE;DRUG_ACCUMULATION;
METHADONE;CYP2C19;rs1267723490;C;LADME-PK;DECREASED_CLEARANCE;DRUG_ACCUMULATION;
FLUOXETINE;CYP2C19;rs1267723490;C;LADME-PK;DECREASED_CLEARANCE;DRUG_ACCUMULATION;
DACARBAZINE;CYP1A1;CYP1A1*1, CYP1A1*2C;*2C;LADME-PK;DECREASED_CLEARANCE;DRUG_ACCUMULATION;
DACARBAZINE;CYP1A1;CYP1A1*1, CYP1A1*4;*4;LADME-PK;DECREASED_CLEARANCE;DRUG_ACCUMULATION;
;CHD2;rs28458425;TT;OTHER;INCREASED_TRANSCRIPTION;;GENE:ABCB1
OXAZEPAM;;rs1976391;G;OTHER;DECREASED_GLUCURONIDATION;;
;;rs247616;T;OTHER;DECREASED_EXPRESSION;;CETP
;ABCA1;rs2515629;G;;INCREASED_EXPRESSION;;ABCA1
;ABCA1;rs4149297;G;;INCREASED_EXPRESSION;;ABCA1
;ABCA1;rs2472507;C;;INCREASED_EXPRESSION;;ABCA1
;ABCA12;rs10182702;C;;INCREASED_EXPRESSION;;ABCA12
;ABCA12;rs2888327;A;;INCREASED_EXPRESSION;;ABCA12
;ABCA8;rs11656365;T;;DECREASED_EXPRESSION;;ABCA8
;ABCB1;rs1045642;AG + GG;LADME-PK;INCREASED_ACTIVITY;;ABCB1
;;rs1976391;G;OTHER;DECREASED_CONCENTRATIONS;;UGT1A1
;ABCB1;rs1128503;AG + GG;LADME-PK;INCREASED_ACTIVITY;;ABCB1
;ABCB1;rs1045642;AA;OTHER;DECREASED_EXPRESSION;;ABCB1
;ABCB1;rs1128503;AA;OTHER;DECREASED_EXPRESSION;;ABCB1
;ABCB1;rs2032582;AA;OTHER;DECREASED_EXPRESSION;;ABCB1
;ABCB9;rs4148866;T;;INCREASED_EXPRESSION;;ABCB9
;ABCC10;rs2185631;A;;DECREASED_EXPRESSION;;ABCC10
DOCETAXEL;ABCC10;rs2125739;TT;TOXICITY;INCREASED_SENSITIVITY;;
;ABCC10;rs9394952;G;;DECREASED_EXPRESSION;;ABCC10
;ABCC10;rs2487663;A;;DECREASED_EXPRESSION;;ABCC10
;ABCC11;rs11861379;C;LADME-PK;INCREASED_TRANSCRIPTION;;GENE:ABCC11
;ABCB1;rs2032582;AC + CC;LADME-PK;INCREASED_ACTIVITY;;ABCB1
;ABCC2;rs717620;T;;INCREASED_TRANSCRIPTION;;GENE:ABCC2
;;rs6822259;CC;;INCREASED_EXPRESSION;;UGT2B17
;;rs729559;GG;LADME-PK;INCREASED_EXPRESSION;;CYP2D6
;;rs6539870;GG;OTHER;INCREASED_EXPRESSION;;IL1B
;;rs478437;CC;OTHER;INCREASED_EXPRESSION;;USP7
;;rs9999111;C;OTHER;DECREASED_EXPRESSION;;ABCG2
;;rs149713212;A;OTHER;DECREASED_EXPRESSION;;ABCG2
;;rs12508471;G;OTHER;DECREASED_EXPRESSION;;ABCG2
ENDOXIFEN;;rs4386686;C;TOXICITY;INCREASED_SENSITIVITY;;
;;rs4073010;TT;LADME-PK;INCREASED_EXPRESSION;;CYP2D6
;;rs35283911;G;OTHER;INCREASED_EXPRESSION;;HP
;;rs4386686;C;TOXICITY, OTHER;INCREASED_EXPRESSION;;MIRLET7I
TAMOXIFEN;;rs478437;CC;OTHER;INCREASED_SENSITIVITY;;
;;rs2784917;AA;OTHER;INCREASED_EXPRESSION;;WNT5B
;;rs9999111;C;OTHER;DECREASED_EXPRESSION;;ABCG2
;;rs10242455;AG;LADME-PK;INCREASED_TRANSCRIPTION;;GENE:CYP3A5
;;rs446112;AA;OTHER;INCREASED_EXPRESSION;;AGPAT2
;;rs10871454;C;LADME-PK;INCREASED_TRANSCRIPTION;;GENE:VKORC1
;;rs2487030;T;;INCREASED_EXPRESSION;;ABCA1
;;rs4355801;G;;INCREASED_EXPRESSION;;TNFRSF11B
;;rs4285917;G;;DECREASED_EXPRESSION;;ABCD2
;;rs12195350;G;;DECREASED_EXPRESSION;;ABCC10
;;rs4898437;C;;INCREASED_EXPRESSION;;ABCD1
;;rs4386686;C;TOXICITY, OTHER;DECREASED_EXPRESSION;;TRAF1
CLOPIDOGREL;CYP2C19;CYP2C19*1, CYP2C19*28;*28;LADME-PK;INCREASED_CLEARANCE;LIKELIHOOD_THERAPEUTIC_SUCCESS;
;ABCC4;rs11568658;A;LADME-PK;INCREASED_CATALYTIC_ACTIVITY;;ABCC4
MERCAPTOPURINE;ABCC4;rs3765534;TT;TOXICITY, LADME-PK;INCREASED_SENSITIVITY;;
;CACNA1S;rs1800559;T;OTHER;INCREASED_ACTIVITY;;CACNA1S
CAFFEINE;CACNA1S;rs1800559;T;OTHER;INCREASED_SENSITIVITY;;
HALOTHANE, ISOFLURANE;CACNA1S;rs772226819;A;OTHER;INCREASED_SENSITIVITY;;
;CBR3;rs8133052;A;;DECREASED_EXPRESSION;;CBR3
;CBR3;rs1056892;A;;INCREASED_EXPRESSION;;CBR3
;CBS;rs915854;C;OTHER;INCREASED_EXPRESSION;;PKNOX1
;CD38;rs1130169;T;;DECREASED_EXPRESSION;;CD38
;CDA;rs3215400;C/del + del/del;OTHER;INCREASED_EXPRESSION;;CDA
;CDA;rs2072671;CC;OTHER;INCREASED_EXPRESSION;;CDA
DEXAMETHASONE;BCL2L11;rs2241843;AA;TOXICITY;INCREASED_SENSITIVITY;;
;CDA;rs532545;CC;OTHER;DECREASED_ACTIVITY;;CDA
;CDA;rs2072671;AA;OTHER;DECREASED_ACTIVITY;;CDA
;CDA;rs1048977;TT;OTHER;INCREASED_EXPRESSION;;CDA
;CDA;rs602950;AA;OTHER;DECREASED_ACTIVITY;;CDA
;CDA;rs602950;GG;OTHER;INCREASED_EXPRESSION;;CDA
;CDA;rs3215400;del/del;;INCREASED_EXPRESSION;;CDA
PALBOCICLIB;CDKN2A;rs759922342;C;EFFICACY;INCREASED_SENSITIVITY;;
REMIMAZOLAM;CES1;rs71647871;T;LADME-PK;DECREASED_METABOLISM;;
CLOPIDOGREL, ENALAPRIL, SACUBITRIL;CES1;rs201065375;A;LADME-PK;DECREASED_METABOLISM;;
;CETP;rs708272;GG;OTHER;INCREASED_EXPRESSION;;CETP
;CDA;rs532545;TT;OTHER;INCREASED_EXPRESSION;;CDA
MERCAPTOPURINE;ABCC4;ABCC4 deficiency;;TOXICITY, LADME-PK;INCREASED_CONCENTRATIONS;;
DEXAMETHASONE;BCL2L11;rs724710;CC;TOXICITY;INCREASED_SENSITIVITY;;
;ARNT;rs2134688;GG;LADME-PK;DECREASED_CONCENTRATIONS;;CYP3A4
;ABCC4;rs11568684;C;LADME-PK;INCREASED_CATALYTIC_ACTIVITY;;ABCC4
;ABCC4;rs4773866;T;;INCREASED_EXPRESSION;;ABCC4
;ABCC9;rs704212;T;OTHER;INCREASED_EXPRESSION;;ABCC9
;ABCD1, BCAP31;rs17091297;C;;INCREASED_EXPRESSION;;ABCD1
;ABCD2;rs4284427;C;;DECREASED_EXPRESSION;;ABCD2
;ABCG2;rs2725263;C;OTHER;INCREASED_EXPRESSION;;ABCG2
;ACE;rs1799752;del;;INCREASED_ENZYME_ACTIVITY;;ACE
;ADCYAP1;rs304400;AA;OTHER;INCREASED_TRANSCRIPTION;;GENE:ABCB1
LOSARTAN;AGTR1;rs12721226;A;OTHER;DECREASED_AFFINITY;TOLERANCE;
;ATP2B1;rs12817819;CT + TT;;DECREASED_EXPRESSION;;ATP2B1
DOXORUBICINOL;AKR1A1;rs2229540;G;LADME-PK;DECREASED_FORMATION;LIKELIHOOD_LESS_CARDIOTOXICITY;
DAUNORUBICINOL;AKR1A1;rs6690497;C;LADME-PK;DECREASED_FORMATION;LIKELIHOOD_LESS_CARDIOTOXICITY;
DAUNORUBICINOL;AKR1A1;rs2229540;G;LADME-PK;DECREASED_FORMATION;LIKELIHOOD_LESS_CARDIOTOXICITY;
EXEMESTANE;AKR1C3;rs62621365;T;LADME-PK;DECREASED_AFFINITY;;
DOXORUBICIN;AKR1C3;rs62621365;T;LADME-PK;DECREASED_CLEARANCE;DRUG_ACCUMULATION;
DOXORUBICIN;AKR1C3;rs34186955;T;LADME-PK;DECREASED_CLEARANCE;DRUG_ACCUMULATION;
DOXORUBICIN;AKR1C3;rs28943579;A;LADME-PK;DECREASED_CLEARANCE;DRUG_ACCUMULATION;
EXEMESTANE;AKR1C4;rs11253043;A;LADME-PK;DECREASED_AFFINITY;;
;ALDH1A2;rs12915901;AA + AG;OTHER;DECREASED_EXPRESSION;;ENZYME:ALDH1A2
;AMPH;rs12701634;CC;OTHER;INCREASED_TRANSCRIPTION;;PROTEIN:MDR
DOXORUBICINOL;AKR1A1;rs6690497;C;LADME-PK;DECREASED_FORMATION;;
;DPYD;rs2297595;C;LADME-PK;DECREASED_ACTIVITY;DRUG_ACCUMULATION;ENZIME:DPD
;ENZYME:CYP2C19;CYP2C19*1, CYP2C19*19;*19;OTHER;DECREASED_EXPRESSION;;ENZYME:CYP2C19
SERTRALINE;CYP2C19;CYP2C19*1, CYP2C19*13;*13;LADME-PK;DECREASED_SENSITIVITY;LIKELIHOOD_THERAPEUTIC_FAILURE;ENZYME:CYP2C19
EBASTINE, TERFENADINE;CYP2J2;rs201379188;A;LADME-PK;DECREASED_CLEARANCE;DRUG_ACCUMULATION;
TERFENADINE;CYP2J2;rs199717190;A;LADME-PK;DECREASED_CLEARANCE;DRUG_ACCUMULATION;
OXYCODONE;CYP3A4;CYP3A4*1, CYP3A4*2, CYP3A4*3, CYP3A4*4, CYP3A4*5, CYP3A4*7, CYP3A4*8, CYP3A4*9, CYP3A4*10, CYP3A4*11, CYP3A4*12, CYP3A4*13, CYP3A4*14, CYP3A4*15, CYP3A4*16, CYP3A4*18, CYP3A4*19, CYP3A4*23, CYP3A4*24, CYP3A4*28, CYP3A4*29, CYP3A4*31, CYP3A4*32, CYP3A4*33, CYP3A4*34;*2 + *3 + *4+ *5 + *7 + *8 + *9 + *10 + *11 + *12 + *13 + *14 + *15 + *16 + *18 + *19 + *23 + *24 + *28 + *29 + *31 + *32 + *33 + *34;LADME-PK;DECREASED_CLEARANCE;DRUG_ACCUMULATION;
OXYCODONE;CYP3A4;CYP3A4*1, CYP3A4*6, CYP3A4*17, CYP3A4*20, CYP3A4*21, CYP3A4*26, CYP3A4*30;*6 + *17 + *20 + *21 + *26 + *30;LADME-PK;DECREASED_CLEARANCE;DRUG_ACCUMULATION;
SIROLIMUS;CYP3A4;CYP3A4*1, CYP3A4*22;*1/*22 + *22/*22;LADME-PK;DECREASED_CLEARANCE;DRUG_ACCUMULATION;
SILDENAFIL;CYP3A4;CYP3A4*1, CYP3A4*3, CYP3A4*10, CYP3A4*14, CYP3A4*32;*3 + *10 + *14 + *32;LADME-PK;INCREASED_CLEARANCE;LIKELIHOOD_THERAPEUTIC_SUCCESS;
IBRUTINIB;CYP3A4;CYP3A4*1, CYP3A4*2, CYP3A4*5, CYP3A4*14, CYP3A4*15, CYP3A4*16, CYP3A4*28, CYP3A4*29, CYP3A4*31, CYP3A4*32;*2 + *5 + *14 + *15 + *16 + *28 + *29 + *31+ *32;LADME-PK;DECREASED_CLEARANCE;DRUG_ACCUMULATION;
;CYP3A4;rs2242480;TT;LADME-PK;DECREASED_ACTIVITY;DRUG_ACCUMULATION;CYP3A4
TESTOSTERONE;CYP3A4;CYP3A4*1, CYP3A4*2, CYP3A4*3, CYP3A4*11, CYP3A4*15, CYP3A4*31;*2 + *3 + *11 + *15 + *31;LADME-PK;INCREASED_CLEARANCE;LIKELIHOOD_THERAPEUTIC_SUCCESS;
TESTOSTERONE;CYP3A4;CYP3A4*1, CYP3A4*5, CYP3A4*10, CYP3A4*14, CYP3A4*16, CYP3A4*17, CYP3A4*23, CYP3A4*24, CYP3A4*28, CYP3A4*29, CYP3A4*32, CYP3A4*33, CYP3A4*34;*5 + *10 + *14 + *16 + *17 + *23 + *24 + *28 +*29 + *32 + *33 + *34;LADME-PK;DECREASED_CLEARANCE;DRUG_ACCUMULATION;
LIDOCAINE;CYP3A4;CYP3A4*1, CYP3A4*2, CYP3A4*5, CYP3A4*9, CYP3A4*16, CYP3A4*24;*2 + *5 + *9 + *16 + *24;LADME-PK;DECREASED_CLEARANCE;DRUG_ACCUMULATION;
MIDAZOLAM;CYP3A4;rs12721627;C;LADME-PK;DECREASED_CLEARANCE;DRUG_ACCUMULATION;
FENTANYL;CYP3A4;rs2242480;T/T;LADME-PK;DECREASED_METABOLISM;;
REGORAFENIB;CYP3A4;CYP3A4*1, CYP3A4*2, CYP3A4*3, CYP3A4*4, CYP3A4*7, CYP3A4*8, CYP3A4*9, CYP3A4*10, CYP3A4*11, CYP3A4*12, CYP3A4*13, CYP3A4*17, CYP3A4*18, CYP3A4*23, CYP3A4*32, CYP3A4*33, CYP3A4*34;*2 + *3 + *4 + *7 + *8 + *9 + *10 + *11 + *12 + *13 + *17 + *18 + *23 + *32 + *33 + *34;LADME-PK;DECREASED_CLEARANCE;DRUG_ACCUMULATION;
TICAGRELOR;CYP3A4;CYP3A4*1, CYP3A4*11, CYP3A4*18, CYP3A4*33;*11 + *18 + *33;LADME-PK;INCREASED_CLEARANCE;LIKELIHOOD_THERAPEUTIC_SUCCESS;
TICAGRELOR;CYP3A4;CYP3A4*1, CYP3A4*2, CYP3A4*3, CYP3A4*4, CYP3A4*5, CYP3A4*9, CYP3A4*14, CYP3A4*15, CYP3A4*16, CYP3A4*17, CYP3A4*19, CYP3A4*24, CYP3A4*28, CYP3A4*29, CYP3A4*31;*2 + *3 + *4 + *5 + *9 + *14 + *15 + *16 + *17 + *19 + *24 + *28 + *29 + *31;LADME-PK;DECREASED_CLEARANCE;DRUG_ACCUMULATION;
LURASIDONE;CYP3A4;CYP3A4*1, CYP3A4*12;*12;LADME-PK;DECREASED_CLEARANCE;DRUG_ACCUMULATION;
LURASIDONE;CYP3A4;CYP3A4*1, CYP3A4*15, CYP3A4*19, CYP3A4*23, CYP3A4*24, CYP3A4*28, CYP3A4*29, CYP3A4*32, CYP3A4*33;*15 + *19 + *23 + *24 + *28 + *29 + *32 + *33;LADME-PK;INCREASED_CLEARANCE;LIKELIHOOD_THERAPEUTIC_SUCCESS;
SAXAGLIPTIN;CYP3A4;CYP3A4*1, CYP3A4*2, CYP3A4*3, CYP3A4*4, CYP3A4*5, CYP3A4*7, CYP3A4*8, CYP3A4*9, CYP3A4*10, CYP3A4*11, CYP3A4*12, CYP3A4*13, CYP3A4*14, CYP3A4*15, CYP3A4*16, CYP3A4*17, CYP3A4*18, CYP3A4*19, CYP3A4*20, CYP3A4*23, CYP3A4*24, CYP3A4*28, CYP3A4*29, CYP3A4*31, CYP3A4*32, CYP3A4*34;*2 + *3 + *4 + *5 + *7 + *8 + *9 + *10 + *11 + *12 + *13 +  *14 + *15 + *16 + *17 + *18 + *19 + *20 + *23 + *24 + *28 + *29 + *31 + *32 + *34;LADME-PK;DECREASED_CLEARANCE;DRUG_ACCUMULATION;
EBASTINE, TERFENADINE;CYP2J2;rs759510111;A;LADME-PK;INCREASED_CLEARANCE;LIKELIHOOD_THERAPEUTIC_SUCCESS;
EBASTINE;CYP2J2;rs757528200;(CTC)1;LADME-PK;DECREASED_CLEARANCE;DRUG_ACCUMULATION;
;CYP2E1;CYP2E1*7A, CYP2E1*7B;*7B;LADME-PK;INCREASED_TRANSCRIPTION;;GENE:CYP2E1
;CYP2E1;CYP2E1*7, CYP2E1*7A;*7A;LADME-PK;INCREASED_TRANSCRIPTION;;GENE:CYP2E1
N-DESMETHYLTAMOXIFEN;CYP2D6;CYP2D6*1, CYP2D6*2, CYP2D6*28, CYP2D6*35;*2 + *28 + *35;LADME-PK;DECREASED_METABOLISM;;
BUFURALOL, DEBRISOQUINE, DEXTROMETHORPHAN;CYP2D6;CYP2D6*1, CYP2D6*17;*17;LADME-PK;DECREASED_CLEARANCE;DRUG_ACCUMULATION;
;CYP2D6;CYP2D6*1, CYP2D6*4;*1/*4;LADME-PK;DECREASED_EXPRESSION;;CYP2D6
DEXTROMETHORPHAN;CYP2D6;CYP2D6*1, CYP2D6*169;*169;LADME-PK;DECREASED_CLEARANCE;DRUG_ACCUMULATION;
DEXTROMETHORPHAN;CYP2D6;rs76187628;G;LADME-PK;INCREASED_CLEARANCE;LIKELIHOOD_THERAPEUTIC_SUCCESS;
;CYP2D6;CYP2D6*1, CYP2D6*169;*169;LADME-PK;DECREASED_EXPRESSION;;CYP2D6
;CYP2D6;rs76187628;G;LADME-PK;INCREASED_EXPRESSION;;CYP2D6
DEXTROMETHORPHAN;CYP2D6;CYP2D6*1, CYP2D6*2;*2;LADME-PK;DECREASED_CLEARANCE;DRUG_ACCUMULATION;
DEXTROMETHORPHAN;CYP2D6;CYP2D6*1, CYP2D6*10;*10;LADME-PK;DECREASED_CLEARANCE;DRUG_ACCUMULATION;
IBRUTINIB;CYP3A4;CYP3A4*1, CYP3A4*3, CYP3A4*4, CYP3A4*9, CYP3A4*19, CYP3A4*34;*3 + *4 + *9 + *19 +*34;LADME-PK;INCREASED_CLEARANCE;LIKELIHOOD_THERAPEUTIC_SUCCESS;
RISPERIDONE;CYP2D6;CYP2D6*1, CYP2D6*2, CYP2D6*28, CYP2D6*35;*2 + *28 + *35;LADME-PK;DECREASED_METABOLISM;;
DEXTROMETHORPHAN;CYP2D6;CYP2D6*1, CYP2D6*26;*26;LADME-PK;DECREASED_CLEARANCE;DRUG_ACCUMULATION;
BUFURALOL, DEXTROMETHORPHAN;CYP2D6;rs750996195;T;LADME-PK;DECREASED_CLEARANCE;DRUG_ACCUMULATION;
BUFURALOL, DEXTROMETHORPHAN;CYP2D6;CYP2D6*1, CYP2D6*17;*17;LADME-PK;DECREASED_CLEARANCE;DRUG_ACCUMULATION;
BUFURALOL;CYP2D6;CYP2D6*1, CYP2D6*14;*14;LADME-PK;DECREASED_CLEARANCE;DRUG_ACCUMULATION;
N-DESMETHYLTAMOXIFEN;CYP2D6;CYP2D6*1, CYP2D6*53;*53;LADME-PK;INCREASED_CLEARANCE;LIKELIHOOD_THERAPEUTIC_SUCCESS;
DAPOXETINE;CYP2D6;CYP2D6*1, CYP2D6*2, CYP2D6*10, CYP2D6*87, CYP2D6*88, CYP2D6*91, CYP2D6*93, CYP2D6*95, CYP2D6*97, CYP2D6*98;*2 + *10 + *87 + *88 + *91 + *93 + *95 + *97 + *98;LADME-PK;DECREASED_CLEARANCE;DRUG_ACCUMULATION;
BUFURALOL;CYP2D6;CYP2D6*1, CYP2D6*53;*53;LADME-PK;INCREASED_CLEARANCE;LIKELIHOOD_THERAPEUTIC_SUCCESS;
DEXTROMETHORPHAN;CYP2D6;CYP2D6*1, CYP2D6*10;*10/*10;LADME-PK;DECREASED_CLEARANCE;DRUG_ACCUMULATION;
;CYP2E1;rs2515641;T;OTHER;DECREASED_EXPRESSION;;CYP2E1
;ZBED5;rs10840501;GG;OTHER;INCREASED_TRANSCRIPTION;;GENE:ABCB1
REGORAFENIB;CYP3A4;CYP3A4*1, CYP3A4*14, CYP3A4*15, CYP3A4*28, CYP3A4*31;*14 + *15 + *28 + *31;LADME-PK;INCREASED_CLEARANCE;LIKELIHOOD_THERAPEUTIC_SUCCESS;
LIDOCAINE;CYP3A4;CYP3A4*1, CYP3A4*11, CYP3A4*14, CYP3A4*15, CYP3A4*18, CYP3A4*19, CYP3A4*23, CYP3A4*29, CYP3A4*31, CYP3A4*32, CYP3A4*34;*11 + *14 + *15 + *18 + *19 + *23 + *29 + *31 + *32 + *34;LADME-PK;INCREASED_CLEARANCE;LIKELIHOOD_THERAPEUTIC_SUCCESS;
CABOZANTINIB;CYP3A4;CYP3A4*1, CYP3A4*14, CYP3A4*15;*14 + *15;LADME-PK;INCREASED_CLEARANCE;LIKELIHOOD_THERAPEUTIC_SUCCESS;
VITAMIN E;CYP4F2;rs2108622;T;LADME-PK;INCREASED_STEADY-STATE-LEVEL;;
;CYP4F2;rs2189784;A;OTHER;INCREASED_EXPRESSION;METABOLISM;ENZYME:CYP4F2
;CYP4F2;rs2189784;A;OTHER;DECREASED_EXPRESSION;;ENZYME:CYP4F12
;CYP4F2;rs2108622;CT;OTHER;INCREASED_CONCENTRATIONS;;ENZYME:CYP4F2
VITAMIN K AND ANALOGUES;CYP4F2;rs2108622;CT + TT;OTHER, LADME-PK;INCREASED_CONCENTRATIONS;;
;CYP4F2;rs2108622;T;OTHER;INCREASED_EXPRESSION;METABOLISM;ENZYME:CYP4F2
;CYP4F2;rs2108622;T;OTHER;INCREASED_EXPRESSION;METABOLISM;ENZYME:CYP4F11
;DCK;rs2306744;T;OTHER;INCREASED_EXPRESSION;;ENZYME: DCK
;DHRS4L1;rs10147475;GG;OTHER;INCREASED_TRANSCRIPTION;;GENE:ABCB1
VITAMIN E;CYP4F2;rs2108622;T;LADME-PK;INCREASED_STEADY-STATE-LEVEL;;
;DISP1;rs61840266;TT;OTHER;INCREASED_TRANSCRIPTION;;GENE:ABCC1
;DPYD;rs568132506;A;OTHER;DECREASED_CATALYTIC_ACTIVITY;INCREASED_RISK;DPYD
;DPYD;rs760663364;A;OTHER;DECREASED_CATALYTIC_ACTIVITY;INCREASED_RISK;DPYD
FLUOROURACIL;DPYD;rs1801159;CC;TOXICITY, LADME-PK;DECREASED_CLEARANCE;DRUG_ACCUMULATION;
;DPYD;rs3918290;CT;OTHER;DECREASED_ACTIVITY;DRUG_ACCUMULATION;ENZIME:DPD
;DPYD;rs1801158;CT;OTHER;DECREASED_CATALYTIC_ACTIVITY;INCREASED_RISK;DPYD
;DPYD;rs547099198;A;OTHER;DECREASED_CATALYTIC_ACTIVITY;INCREASED_RISK;DPYD
;DPYD;rs67376798;AT;OTHER;DECREASED_CATALYTIC_ACTIVITY;INCREASED_RISK;DPYD
;DPYD;rs1801265;G;OTHER;DECREASED_ACTIVITY;DRUG_ACCUMULATION;ENZIME:DPD
;DPYD;rs1801160;T;OTHER;DECREASED_ACTIVITY;DRUG_ACCUMULATION;ENZIME:DPD
;DISP1;rs17535305;GG;OTHER;INCREASED_TRANSCRIPTION;;GENE:ABCB1
BUFURALOL, DEXTROMETHORPHAN;CYP2D6;rs777560972;A;LADME-PK;DECREASED_CLEARANCE;DRUG_ACCUMULATION;
;CYP4F11;rs1060467;A;OTHER;INCREASED_EXPRESSION;METABOLISM;CYP4F2
;CYP3A5;CYP3A5*1, CYP3A5*3;*3/*3;OTHER;DECREASED_EXPRESSION;;CYP3A5
BREXPIPRAZOLE;CYP3A4;CYP3A4*1, CYP3A4*14, CYP3A4*15;*14 + *15;LADME-PK;INCREASED_CLEARANCE;LIKELIHOOD_THERAPEUTIC_SUCCESS;
ALECTINIB;CYP3A4;CYP3A4*1, CYP3A4*4, CYP3A4*7, CYP3A4*8, CYP3A4*12, CYP3A4*14, CYP3A4*16, CYP3A4*17, CYP3A4*18, CYP3A4*19, CYP3A4*20, CYP3A4*23, CYP3A4*24;*4 + *7 + *8 + *12 + *14 + *16 + *17 + *18 + *19 + *20 + *23 + *24;LADME-PK;DECREASED_METABOLISM;;
METHADONE;CYP3A4;CYP3A4*1, CYP3A4*2, CYP3A4*3, CYP3A4*5, CYP3A4*14, CYP3A4*15, CYP3A4*16, CYP3A4*17, CYP3A4*18, CYP3A4*19, CYP3A4*24, CYP3A4*29, CYP3A4*31;*2 + *3  + *5  + *14 + *15 + *16 + *17 + *18 + *19 + *24 + *29 + *31;LADME-PK;DECREASED_CLEARANCE;DRUG_ACCUMULATION;
METHADONE;CYP3A4;CYP3A4*1, CYP3A4*11, CYP3A4*32, CYP3A4*34;*11 + *32 + *34;LADME-PK;INCREASED_CLEARANCE;LIKELIHOOD_THERAPEUTIC_SUCCESS;
;CYP3A4;rs35599367;A;OTHER;DECREASED_EXPRESSION;;CYP3A4
MIDAZOLAM;CYP3A4;CYP3A4*1, CYP3A4*39, CYP3A4*40, CYP3A4*41, CYP3A4*42, CYP3A4*43, CYP3A4*44, CYP3A4*46;*39 + *40 + *41 + *42 + *43 + *44 + *46;LADME-PK;DECREASED_CLEARANCE;DRUG_ACCUMULATION;
MACITENTAN;CYP3A4;CYP3A4*1, CYP3A4*3, CYP3A4*4, CYP3A4*5, CYP3A4*10, CYP3A4*15, CYP3A4*16;*3 + *4 + *5 + *10 +*15 + *16;LADME-PK;INCREASED_CLEARANCE;LIKELIHOOD_THERAPEUTIC_SUCCESS;
;CYP3A4;rs4986909;A;;DECREASED_STEADY-STATE-LEVEL;;CYP3A4
VANDETANIB;CYP3A4;CYP3A4*1, CYP3A4*5, CYP3A4*7, CYP3A4*8, CYP3A4*10, CYP3A4*11, CYP3A4*12, CYP3A4*13, CYP3A4*14, CYP3A4*17, CYP3A4*18, CYP3A4*19, CYP3A4*20, CYP3A4*23, CYP3A4*24, CYP3A4*31, CYP3A4*34;*5 + *7 + *8 + *10 + *11 + *12 + *13 + *14 + *17 + *18 + *19 + *20 + *23 + *24 + *31 + *34;LADME-PK;DECREASED_CLEARANCE;DRUG_ACCUMULATION;
;CYP3A5;CYP3A5*1, CYP3A5*3;*3/*3;OTHER;DECREASED_EXPRESSION;;CYP3A5
CABOZANTINIB;CYP3A4;CYP3A4*1, CYP3A4*2, CYP3A4*3, CYP3A4*4, CYP3A4*5, CYP3A4*7, CYP3A4*8, CYP3A4*9, CYP3A4*11, CYP3A4*12, CYP3A4*13, CYP3A4*16, CYP3A4*17, CYP3A4*18, CYP3A4*19, CYP3A4*23, CYP3A4*24, CYP3A4*28, CYP3A4*29, CYP3A4*31, CYP3A4*32, CYP3A4*33, CYP3A4*34;*2 + *3 + *4 + *5 + *7 + *8 + *9 + *11 + *12 + *13 + *16 + *17 + *18 + *19 + *23 + *24+ *28 + *29 + *31 + *32 + *33 + *34;LADME-PK;DECREASED_CLEARANCE;DRUG_ACCUMULATION;
AMIODARONE;CYP3A4;CYP3A4*1, CYP3A4*2, CYP3A4*9, CYP3A4*10, CYP3A4*11, CYP3A4*16, CYP3A4*18, CYP3A4*19, CYP3A4*23, CYP3A4*29, CYP3A4*31, CYP3A4*32, CYP3A4*34;*2 + *9 + *10 + *11 + *16 + *18 + *19 + *23 + *29 + *31 + *32 + *34;LADME-PK;INCREASED_CLEARANCE;LIKELIHOOD_THERAPEUTIC_SUCCESS;
SILDENAFIL;CYP3A4;CYP3A4*1, CYP3A4*2, CYP3A4*5, CYP3A4*24, CYP3A4*28, CYP3A4*29;*2 + *5 + *24 + *28 + *29;LADME-PK;DECREASED_CLEARANCE;DRUG_ACCUMULATION;
;CYP3A4;CYP3A4*8;*8;;DECREASED_STEADY-STATE-LEVEL;;CYP3A4
BREXPIPRAZOLE;CYP3A4;CYP3A4*1, CYP3A4*3, CYP3A4*4, CYP3A4*5, CYP3A4*9, CYP3A4*10, CYP3A4*11, CYP3A4*12, CYP3A4*13, CYP3A4*16, CYP3A4*18, CYP3A4*23, CYP3A4*29, CYP3A4*31, CYP3A4*32, CYP3A4*33, CYP3A4*34;*3 + *4 + *5 + *9 + *10 + *11 + *12 + *13 + *16 + *18 + *23 + *29 + *31 + *32 + *33 + *34;LADME-PK;DECREASED_CLEARANCE;DRUG_ACCUMULATION;
;CYP3A4;CYP3A4*12;*12;;DECREASED_ENZYME_ACTIVITY;;CYP3A4
BREXPIPRAZOLE;CYP3A4;CYP3A4*1, CYP3A4*2, CYP3A4*7, CYP3A4*8, CYP3A4*17, CYP3A4*20;*2 + *7 + *8 + *17 + *20;LADME-PK;DECREASED_CLEARANCE;DRUG_ACCUMULATION;
;CYP3A4;CYP3A4*11;*11;;DECREASED_STEADY-STATE-LEVEL;;CYP3A4
AMIODARONE;CYP3A4;CYP3A4*1, CYP3A4*17, CYP3A4*24;*17 + *24;LADME-PK;DECREASED_CLEARANCE;DRUG_ACCUMULATION;
MIDAZOLAM;CYP3A5;CYP3A5*1, CYP3A5*3;*1/*1;LADME-PK;INCREASED_METABOLISM;;
MACITENTAN;CYP3A4;CYP3A4*1, CYP3A4*9, CYP3A4*11, CYP3A4*12, CYP3A4*13, CYP3A4*17, CYP3A4*20, CYP3A4*23, CYP3A4*24, CYP3A4*28, CYP3A4*29, CYP3A4*33, CYP3A4*34;*9 + *11 + *12 + *13 +*17 + *20 + *23 + *24 + *28 + *29 + *33 + *34;LADME-PK;DECREASED_CLEARANCE;DRUG_ACCUMULATION;
BUFURALOL, DEXTROMETHORPHAN;CYP2D6;rs138417770;T;LADME-PK;DECREASED_CLEARANCE;DRUG_ACCUMULATION;
BUFURALOL, DEXTROMETHORPHAN;CYP2D6;rs371793722;G;LADME-PK;DECREASED_CLEARANCE;DRUG_ACCUMULATION;
METHADONE;CYP2C19;rs181297724;C;LADME-PK;DECREASED_CLEARANCE;DRUG_ACCUMULATION;
METHADONE;CYP2C19;CYP2C19*1, CYP2C19*29, CYP2C19*30, CYP2C19*31, CYP2C19*32, CYP2C19*33;*29 + *30 + *31 + *32 + *33;LADME-PK;DECREASED_CLEARANCE;DRUG_ACCUMULATION;
VORICONAZOLE;CYP2C19;rs778258371;A;LADME-PK;DECREASED_CLEARANCE;DRUG_ACCUMULATION;
FLUOXETINE;CYP2C19;CYP2C19*1, CYP2C19*32;*32;LADME-PK;DECREASED_CLEARANCE;DRUG_ACCUMULATION;
VORICONAZOLE;CYP2C19;CYP2C19*1, CYP2C19*2;*2;LADME-PK;DECREASED_CLEARANCE;DRUG_ACCUMULATION;
VORICONAZOLE;CYP2C19;CYP2C19*1, CYP2C19*3;*3;LADME-PK;DECREASED_CLEARANCE;DRUG_ACCUMULATION;
METHADONE;CYP2C19;rs138142612;A;LADME-PK;DECREASED_CLEARANCE;DRUG_ACCUMULATION;
MEPHENYTOIN, OMEPRAZOLE;CYP2C19;CYP2C19*1, CYP2C19*24;*24;LADME-PK;DECREASED_CLEARANCE;DRUG_ACCUMULATION;
VORICONAZOLE;CYP2C19;CYP2C19*1, CYP2C19*32;*32;LADME-PK;DECREASED_CLEARANCE;DRUG_ACCUMULATION;
FLUOXETINE;CYP2C19;CYP2C19*1, CYP2C19*31;*31;LADME-PK;DECREASED_CLEARANCE;DRUG_ACCUMULATION;
16ALPHA-HYDROXYTESTOSTERONE;CYP2C19;CYP2C19*1, CYP2C19*11, CYP2C19*23;*11 + *23;LADME-PK;INCREASED_FORMATION;;
11ALPHA-HYDROXYTESTOSTERONE;CYP2C19;CYP2C19*1, CYP2C19*9, CYP2C19*11, CYP2C19*23;*9 + *11 + *23;LADME-PK;INCREASED_FORMATION;;
VORICONAZOLE;CYP2C19;CYP2C19*1, CYP2C19*29;*29;LADME-PK;DECREASED_CLEARANCE;DRUG_ACCUMULATION;
FLUOXETINE;CYP2C19;CYP2C19*1, CYP2C19*29;*29;LADME-PK;DECREASED_CLEARANCE;DRUG_ACCUMULATION;
VORICONAZOLE;CYP2C19;CYP2C19*1, CYP2C19*31;*31;LADME-PK;DECREASED_CLEARANCE;DRUG_ACCUMULATION;
VORICONAZOLE;CYP2C19;CYP2C19*1, CYP2C19*30;*30;LADME-PK;DECREASED_CLEARANCE;DRUG_ACCUMULATION;
SIPONIMOD;CYP2C9;CYP2C9*2, CYP2C9*3;*3/*3 + *2/*2;LADME-PK;DECREASED_METABOLISM;;
DICLOFENAC;CYP2C9;CYP2C9*13;*13;LADME-PK;DECREASED_CLEARANCE;DRUG_ACCUMULATION;
DICLOFENAC;CYP2C9;CYP2C9*3;*3;LADME-PK;DECREASED_CLEARANCE;DRUG_ACCUMULATION;
TOLBUTAMIDE;CYP2C9;CYP2C9*3;*1/*3;LADME-PK;DECREASED_CLEARANCE;DRUG_ACCUMULATION;
ANDROSTENEDIONE;CYP2C19;CYP2C19*1, CYP2C19*9, CYP2C19*11, CYP2C19*23;*9 + *11 + *23;LADME-PK;INCREASED_FORMATION;;
PHENYTOIN;CYP2C9;CYP2C9*52;*52;LADME-PK;DECREASED_CLEARANCE;DRUG_ACCUMULATION;
METHADONE;CYP2C19;rs749678783;C;LADME-PK;DECREASED_CLEARANCE;DRUG_ACCUMULATION;
METHADONE;CYP2C19;rs770829708;A;LADME-PK;DECREASED_CLEARANCE;DRUG_ACCUMULATION;
FLUOXETINE;CYP2C19;rs72552267;A;LADME-PK;DECREASED_CLEARANCE;DRUG_ACCUMULATION;
METHADONE;CYP2C19;rs200150287;G;LADME-PK;DECREASED_CLEARANCE;DRUG_ACCUMULATION;
FLUOXETINE;CYP2C19;rs749678783;C;LADME-PK;DECREASED_CLEARANCE;DRUG_ACCUMULATION;
FLUOXETINE;CYP2C19;rs138142612;A;LADME-PK;DECREASED_CLEARANCE;DRUG_ACCUMULATION;
FLUOXETINE;CYP2C19;rs181297724;C;LADME-PK;DECREASED_CLEARANCE;DRUG_ACCUMULATION;
FLUOXETINE, KETOCONAZOLE, SERTRALINE, TICLOPIDINE;CYP2C19;rs181297724;C;LADME-PK;DECREASED_SENSITIVITY;LIKELIHOOD_THERAPEUTIC_FAILURE;
FLUVOXAMINE, OMEPRAZOLE;CYP2C19;rs181297724;C;LADME-PK;INCREASED_SENSITIVITY;;
FLUOXETINE;CYP2C19;rs17878459;C;LADME-PK;DECREASED_SENSITIVITY;LIKELIHOOD_THERAPEUTIC_FAILURE;
CELECOXIB, FLUCONAZOLE, FLUVOXAMINE;CYP2C19;rs17878459;C;LADME-PK;INCREASED_SENSITIVITY;LIKELIHOOD_THERAPEUTIC_SUCCESS;
MEPHENYTOIN;CYP2C19;CYP2C19*1, CYP2C19*23;*23;LADME-PK;INCREASED_CLEARANCE;LIKELIHOOD_THERAPEUTIC_SUCCESS;
FLUVOXAMINE;CYP2C19;rs3758581;G;LADME-PK;INCREASED_SENSITIVITY;;
VORICONAZOLE;CYP2C19;rs763625282;A;LADME-PK;DECREASED_CLEARANCE;DRUG_ACCUMULATION;
VORICONAZOLE;CYP2C19;rs3758581;G;LADME-PK;DECREASED_CLEARANCE;DRUG_ACCUMULATION;
OMEPRAZOLE;CYP2C19;CYP2C19*1, CYP2C19*19;*19;LADME-PK;DECREASED_AFFINITY;TOLERANCE/LESS_EFFICACY;ENZYME:CYP2C19
VORICONAZOLE;CYP2C19;rs770829708;A;LADME-PK;DECREASED_CLEARANCE;DRUG_ACCUMULATION;
CELECOXIB, FLUCONAZOLE;CYP2C19;CYP2C19*1, CYP2C19*14;*14;LADME-PK;INCREASED_SENSITIVITY;;
FLUOXETINE, SERTRALINE;CYP2C19;CYP2C19*1, CYP2C19*14;*14;LADME-PK;DECREASED_SENSITIVITY;LIKELIHOOD_THERAPEUTIC_FAILURE;
FLUCONAZOLE, FLUVOXAMINE;CYP2C19;CYP2C19*1, CYP2C19*13;*13;LADME-PK;INCREASED_SENSITIVITY;;
VORICONAZOLE;CYP2C19;rs181297724;C;LADME-PK;DECREASED_CLEARANCE;DRUG_ACCUMULATION;
METHADONE;CYP2C19;rs200346442;A;LADME-PK;DECREASED_CLEARANCE;DRUG_ACCUMULATION;
VORICONAZOLE;CYP2C19;rs550527959;T;LADME-PK;DECREASED_CLEARANCE;DRUG_ACCUMULATION;
;ENZYME:CYP2C19;rs7902257;A;OTHER;DECREASED_EXPRESSION;;ENZYME:CYP2C19
PHENYTOIN;CYP2C9;CYP2C9*51;*51;LADME-PK;INCREASED_CLEARANCE;LIKELIHOOD_THERAPEUTIC_SUCCESSMETABOLISM;ENZYME:CYP2C9
;ENZYME:CYP2C9;rs4918758;C;OTHER;DECREASED_TRANSCRIPTION;;GENE:CYP2C9
PHENYTOIN;CYP2C9;CYP2C9*33;*33;LADME-PK;DECREASED_CLEARANCE;DRUG_ACCUMULATION;
PHENYTOIN;CYP2C9;CYP2C9*13;*13;LADME-PK;DECREASED_CLEARANCE;DRUG_ACCUMULATION;
PHENYTOIN;CYP2C9;CYP2C9*16;*16;LADME-PK;DECREASED_CLEARANCE;DRUG_ACCUMULATION;
PHENYTOIN;CYP2C9;CYP2C9*45;*45;LADME-PK;DECREASED_CLEARANCE;DRUG_ACCUMULATION;
;CYP2D6;rs16947;AA + AG;OTHER;DECREASED_EXPRESSION;;CYP2D6
PRIMAQUINE;CYP2D6;CYP2D6*1, CYP2D6*22, CYP2D6*26, CYP2D6*48;*22 + *48;LADME-PK;INCREASED_CLEARANCE;LIKELIHOOD_THERAPEUTIC_SUCCESS;
METHADONE;CYP2D6;CYP2D6*1, CYP2D6*2, CYP2D6*10, CYP2D6*87, CYP2D6*89, CYP2D6*90, CYP2D6*93, CYP2D6*95, CYP2D6*97, CYP2D6*98;*2 + *10 + *87 + *89 + *90 + *93 + *95 + *97 + *98;LADME-PK;DECREASED_CLEARANCE;DRUG_ACCUMULATION;
;CYP2D6;CYP2D6*1, CYP2D6*92, CYP2D6*96;*92 + *96;LADME-PK;DECREASED_ACTIVITY;DRUG_ACCUMULATION;CYP2D6
VENLAFAXINE;CYP2D6;CYP2D6*1, CYP2D6*2, CYP2D6*10, CYP2D6*87, CYP2D6*88, CYP2D6*89, CYP2D6*90, CYP2D6*91, CYP2D6*93, CYP2D6*94, CYP2D6*95, CYP2D6*97, CYP2D6*98;*2 + *10 + *87 + *88 + *89 + *90 + *91 + *93 + *94 + *95 + *97 + *98;LADME-PK;DECREASED_CLEARANCE;DRUG_ACCUMULATION;
PHENYTOIN;CYP2C9;CYP2C9*36;*36;LADME-PK;DECREASED_CLEARANCE;DRUG_ACCUMULATION;
GEFITINIB;CYP2D6;CYP2D6*1, CYP2D6*10, CYP2D6*87, CYP2D6*90, CYP2D6*93, CYP2D6*95, CYP2D6*98;*10 + *87 + *90 + *93 + *95 + *98;LADME-PK;DECREASED_CLEARANCE;DRUG_ACCUMULATION;
BUFURALOL;CYP2D6;CYP2D6*1, CYP2D6*2, CYP2D6*10, CYP2D6*87, CYP2D6*88, CYP2D6*89, CYP2D6*90, CYP2D6*91, CYP2D6*93, CYP2D6*94, CYP2D6*95, CYP2D6*97, CYP2D6*98, CYP2D6*134, CYP2D6*153;*2 + *10 + *87 + *88 + *89 + *90 + *91 + *93 + *94 + *95 + *97 + *98 + *134 + *153;LADME-PK;DECREASED_CLEARANCE;DRUG_ACCUMULATION;
RISPERIDONE;CYP2D6;CYP2D6*1, CYP2D6*2, CYP2D6*10, CYP2D6*87, CYP2D6*88, CYP2D6*89, CYP2D6*90, CYP2D6*91, CYP2D6*93, CYP2D6*94, CYP2D6*95, CYP2D6*97, CYP2D6*98;*2 + *10 + *87 + *88 + *89 + *90 + *91 + *93 + *94 + *95 + *97 + *98;LADME-PK;DECREASED_CLEARANCE;DRUG_ACCUMULATION;
CITALOPRAM;CYP2D6;CYP2D6*1, CYP2D6*2, CYP2D6*10, CYP2D6*87, CYP2D6*88, CYP2D6*89, CYP2D6*90, CYP2D6*91, CYP2D6*93, CYP2D6*98;*2 + *10 + *87 + *88 + *89 + *90 + *91 + *93 + *98;LADME-PK;DECREASED_CLEARANCE;DRUG_ACCUMULATION;
ATOMOXETINE;CYP2D6;CYP2D6*1, CYP2D6*2, CYP2D6*10, CYP2D6*87, CYP2D6*88, CYP2D6*90, CYP2D6*91, CYP2D6*93, CYP2D6*95, CYP2D6*97;*90 + *91 + *88 + *97 + *2 + *95 + *87 + *93 + *10;LADME-PK;DECREASED_CLEARANCE;DRUG_ACCUMULATION;
TAMOXIFEN;CYP2D6;CYP2D6*1, CYP2D6*2, CYP2D6*10, CYP2D6*87, CYP2D6*90, CYP2D6*91, CYP2D6*93, CYP2D6*95, CYP2D6*98;*2 + *10 + *87 + *90 + *91 + *93 + *95 + *98;LADME-PK;DECREASED_CLEARANCE;DRUG_ACCUMULATION;
TOLTERODINE;CYP2D6;CYP2D6*1, CYP2D6*10, CYP2D6*93, CYP2D6*94, CYP2D6*95;*10 + *93 + *94 + *95;LADME-PK;DECREASED_CLEARANCE;DRUG_ACCUMULATION;
DEXTROMETHORPHAN;CYP2D6;CYP2D6*1, CYP2D6*87, CYP2D6*90, CYP2D6*91, CYP2D6*93, CYP2D6*94, CYP2D6*95, CYP2D6*97, CYP2D6*98, CYP2D6*134, CYP2D6*153;*87 + *90 + *91 + *93 + *94 + *95 + *97 + *98 + *134 + *153;LADME-PK;DECREASED_CLEARANCE;DRUG_ACCUMULATION;
AMITRIPTYLINE;CYP2D6;CYP2D6*1, CYP2D6*2, CYP2D6*10, CYP2D6*87, CYP2D6*88, CYP2D6*89, CYP2D6*90, CYP2D6*91, CYP2D6*93, CYP2D6*94, CYP2D6*95, CYP2D6*97, CYP2D6*98;*2 + *10 + *87 + *88 + *89 + *90 + *91 + *93 + *94 + *95 + *97 + *98;LADME-PK;DECREASED_CLEARANCE;DRUG_ACCUMULATION;
BUFURALOL, DEXTROMETHORPHAN;CYP2D6;rs745746329;T;LADME-PK;DECREASED_CLEARANCE;DRUG_ACCUMULATION;
OLANZAPINE;CYP2D6;CYP2D6*1, CYP2D6*10, CYP2D6*87, CYP2D6*88, CYP2D6*90, CYP2D6*91, CYP2D6*93, CYP2D6*95, CYP2D6*97;*10 + *87 + *88 + *90 + *91 + *93 + *95 + *97;LADME-PK;DECREASED_CLEARANCE;DRUG_ACCUMULATION;
;ENZYME:CYP2C9;rs9332094;C;OTHER;DECREASED_TRANSCRIPTION;;GENE:CYP2C9
PHENYTOIN;CYP2C9;CYP2C9*37;*37;LADME-PK;DECREASED_CLEARANCE;DRUG_ACCUMULATION;
PHENYTOIN;CYP2C9;CYP2C9*42;*42;LADME-PK;DECREASED_CLEARANCE;DRUG_ACCUMULATION;
;ENZYME:CYP2C9;rs7089580;AT + TT;OTHER;INCREASED_EXPRESSION;;ENZYME:CYP2C9
PHENYTOIN;CYP2C9;CYP2C9*55;*55;LADME-PK;DECREASED_CLEARANCE;DRUG_ACCUMULATION;
PHENYTOIN;CYP2C9;CYP2C9*56;*56;LADME-PK;INCREASED_CLEARANCE;LIKELIHOOD_THERAPEUTIC_SUCCESSMETABOLISM;ENZYME:CYP2C9
PHENYTOIN;CYP2C9;CYP2C9*53;*53;LADME-PK;INCREASED_CLEARANCE;LIKELIHOOD_THERAPEUTIC_SUCCESSMETABOLISM;ENZYME:CYP2C9
PHENYTOIN;CYP2C9;CYP2C9*50;*50;LADME-PK;DECREASED_CLEARANCE;DRUG_ACCUMULATION;
PHENYTOIN;CYP2C9;CYP2C9*54;*54;LADME-PK;INCREASED_CLEARANCE;LIKELIHOOD_THERAPEUTIC_SUCCESSMETABOLISM;ENZYME:CYP2C9
PHENYTOIN;CYP2C9;CYP2C9*19;*19;LADME-PK;DECREASED_CLEARANCE;DRUG_ACCUMULATION;
PHENYTOIN;CYP2C9;CYP2C9*31;*31;LADME-PK;DECREASED_CLEARANCE;DRUG_ACCUMULATION;
LOSARTAN;CYP2C9;rs1057910;C;LADME-PK;DECREASED_CLEARANCE;DRUG_ACCUMULATION;
PHENYTOIN;CYP2C9;CYP2C9*41;*41;LADME-PK;INCREASED_CLEARANCE;LIKELIHOOD_THERAPEUTIC_SUCCESSMETABOLISM;ENZYME:CYP2C9
PHENYTOIN;CYP2C9;CYP2C9*27;*27;LADME-PK;INCREASED_CLEARANCE;LIKELIHOOD_THERAPEUTIC_SUCCESSMETABOLISM;ENZYME:CYP2C9
PHENYTOIN;CYP2C9;CYP2C9*14;*14;LADME-PK;DECREASED_CLEARANCE;DRUG_ACCUMULATION;
DICLOFENAC, LOSARTAN, TOLBUTAMIDE;CYP2C9;CYP2C9*62;*62;LADME-PK;DECREASED_CLEARANCE;DRUG_ACCUMULATION;
DICLOFENAC, LOSARTAN, TOLBUTAMIDE;CYP2C9;CYP2C9*2;*2;LADME-PK;DECREASED_CLEARANCE;DRUG_ACCUMULATION;
DICLOFENAC, LOSARTAN, TOLBUTAMIDE;CYP2C9;CYP2C9*3;*3;LADME-PK;DECREASED_CLEARANCE;DRUG_ACCUMULATION;
PHENYTOIN;CYP2C9;CYP2C9*47;*47;LADME-PK;INCREASED_CLEARANCE;LIKELIHOOD_THERAPEUTIC_SUCCESSMETABOLISM;ENZYME:CYP2C9
PHENYTOIN;CYP2C9;CYP2C9*49;*49;LADME-PK;INCREASED_CLEARANCE;LIKELIHOOD_THERAPEUTIC_SUCCESSMETABOLISM;ENZYME:CYP2C9
PHENYTOIN;CYP2C9;CYP2C9*3;*3;LADME-PK;DECREASED_CLEARANCE;DRUG_ACCUMULATION;
PHENYTOIN;CYP2C9;CYP2C9*43;*43;LADME-PK;DECREASED_CLEARANCE;DRUG_ACCUMULATION;
PHENYTOIN;CYP2C9;CYP2C9*39;*39;LADME-PK;DECREASED_CLEARANCE;DRUG_ACCUMULATION;
PHENYTOIN;CYP2C9;CYP2C9*8;*8;LADME-PK;DECREASED_CLEARANCE;DRUG_ACCUMULATION;
;ZNF890P;rs62442010;AA;OTHER;INCREASED_TRANSCRIPTION;;GENE:ABCB1
